NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR THE V3 LOOP AND CD-4 BINDING SITE OF HIV-1 GP120

Abstract: Anti-HIV-1 antibodies directed against the V3 loop and the CD-4 binding site of gp120 synergistically neutralize. Certain antibodies neutralize the IIIB, MN, SF-2 and RF strains.

Description: NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR THE V3 LOOP AND CD-4 BINDING SITE OF HIV-1 GP120 Field of the Invention This invention relates to antibodies ("Abs") having neutralizing capabilities against HIV-1. Background of The Invention A major problem for immunological approaches to the control of HIV is the extreme variability of the viral genome, which is reflected in a corresponding antigenic variability. This problem has hampered attempts to design effective vaccines as well as attempts to develop i munotherapies. It is, thus, well recognized that the identification of neutralizing but non-variable epitopes would constitute a major advance in this area. The HIV envelope is composed of two glycoproteins, gpl20 and gp41. These glycoproteins are initially synthesized in virus-infected cells as a precursor called gpl60; this molecule is cleaved into gpl20 and gp41 prior to assembly of virions. The latter two glycoproteins are non-covalently associated with each other and are anchored to the viral membrane via gp41, a transme brane protein (reviewed in (Olshevsky et al. 1990)). One region which has been shown to elicit neutralizing antibodies is the V3 region hypervariable loop (hvl-V3) of the gpl20 (amino acids 307-330) ; this is an i munodominant epitope cluster eliciting potent neutralizing Abs in man and experimental animals (summarized in (Javaherian et al. 1990)). Initially, there was the concern that the hypervariability of the V3 loop would prevent the design of a rational vaccine based on this epitope. However, LaRosa et al. (LaRosa et al. 1990) have recently shown that the V3 loop is less variable than originally thought, and, in addition, anti-V3 Abs with broader HIV strain specificity have been generated (Javaherian et al. 1990); these Abs recognize a conserved hexamer sequence (GPGRAF) present at the tip of the ->op. Three anti-V3 human monoclonal antibodies (HuMAbs) have been isolated by other investigators, and each is relatively strain-specific, recognizing only the MN strain of virus and closely related strains (Scott et al. 1990, Zolla-Pazner et al. 1990) . Another epitope cluster of HIV envelope that has been shown to elicit neutralizing antibodies is the CD-4 binding site of gpl20. Recent evidence indicates that the CD-4 binding site is formed by non-contiguous protein loops from multiple regions of gpl20 (Olshevsky et al. 1990) . However, the precise structure of the CD-4 binding site and its contact residues have yet to be defined. Neutralizing antibodies against this site have been raised in some rodents (Sun et al. 1989, Lasky et al. 1987, Berman et al. 1989) using either recombinant gpl20 or linear peptides adjacent to one of the loops apparently forming the CD-4 binding site. It was believed that humans do not produce Abs against the CD-4 binding site, partially because no human serum Abs could be shown to bind to the linear peptides discussed above (Sun et al. 1989, Lasky et al. 1987). We and other groups (Robinson et al. 1990, Posner et 4 al. 1990) have isolated HuMAbs against conformational, rather than linear, epitopes „ 5 mapping in the CD-4 binding region. These HuMAbs have neutralizing activity against a variety of divergent HIV-1 strains and, therefore, recognize relatively conserved epitopes. The human monoclonal antibodies of Robinson et al. i.e., 10 those whose binding is inhibited by CD-4, have been shown to neutralize MN and IIIB strains of HIV-l, among others, but not to neutralize the RF strain. RF is a strain of Haitian origin. There is a need for human mAbs which are as broadly 15 neutralizing as po.v'ble. There is also a need for human mAbs which are as strongly neutralizing of common strains, such as MN, as is possible. Earlier in the AIDS epidemic, there was skepticism about the protective function of 20 neutralizing Abs against HIV, since such Abs could be found in seropositive individuals who went on to develop AIDS. Now it is understood that the titers of neutralizing Abs developed in humans during the course of HIV infection are generally 25 not very high (Robert-Guroff et al. 1985, Weiss et al. 1985), that higher titers of certain anti-HIV Abs do correlate with a better prognosis (Robert-Guroff et al. 1985, Rook et al. 1987, Ljunggren et al. 1987, Ho et al. 1987, Devash et # 30 al. 1990) , and that deleterious Abs against HIV that actually enhance viral infection may be present in seropositive individuals (Robinson et al. 1990, Homsy et al. 1988, Takeda et al. 1988, Jouault et al. 1989). Furthermore, recent studies 35 demonstrate the protective effects of certain anti-HIV Abs in vivo. In one such study, passive administration of hyperimmune plasma from healthy HIV-infected humans to ARC and AIDS patients resulted in sustained clearance of p24 antigen and a maintenance or increase in the recipients 1 anti-viral Ab titer, and clinical improvement was noted in 5 of 9 recipients (Karpas et al. 1988). In another study, chimpanzees were challenged with a stock of the IIIB strain of HIV that had previously been incubated with neutralizing serum Ab from an HIV-seropositive chimpanzee. The challenged animals were protected against viral infection, as assessed by lack of serum Ab response to virus and attempts at viral isolation (Emini et al. 1990) . Very recently, successful long term protection of two chimpanzees against HIV infection has been demons..rated by immunization with recombinant gpl60 followed by a V3 loop peptide (Girard et al. 1991) . In a different study, chimpanzees immunized with recombinant gpl20 and challenged with HIV were also protected from infection (Berman et al. 1990) . In both of these vaccine trials, significant titers of strain-specific neutralizing Ab were induced prior to challenge with virus. The protection obtained is believed to be due primarily to this neutralizing Ab, since εubunit vaccines are thought to be poor inducers of cytotoxic T cells (see (Berman et al. 1990)). Viral neutralization by combinations of rodent mAbs has been described for certain non-AIDS viruses, including rubella (Gerna et al. 1987) , vesicular stomatitis (Volk et al. 1982) , West Nile (Peiris et al. 1982), Sindbis (Clegg et al. 1983), Japanese encephalitis (Kimura-Kuroda and Yasui 1983), La Crosse (Kingsford 1984), Newcastle disease (Russell 1986) , respiratory syncytial (Anderson et al. 1988) , and bovine herpesvirus type 4 (Dubuisson et al. 1990) viruses. In these studies, relatively high levels of viral neutralization are attained by relatively low concentrations of two or more mAbs in combination than is attained by any of the mAbs alone. To our knowledge, however, improved neutralization of HIV by a combination of Abs has not been reported, nor has anyone previously demonstrated synergistic neutralization of any virus by human mAbs. Summary of the Invention The present invention relates to a synergistic combination of certain antibodies specific for HIV-envelope glycoprotein gpl20. One of the Abs in the combination is specific for the V3 loop of HIV-1 envelope glycoprotein gpl20. The other is specific for the CD-4 binding site of HIV-1 envelope glycoprotein gpl20. The invention includes all Abs which are specific for epitopes within these epitope clusters which, when combined, are capable of synergistically neutralizing HIV-1 infection. Preferably the antibodies are human monoclonal antibodies, but the invention relates to other types of antibodies as well. The synergistic combination of human mAbs is preferably capable of achieving 95% neutralization of about 1 x 10 4 infectious units of the MN strain of HIV-l at a concentration of about 0.5 micrograms/ml. Preferred embodiments of the invention include the synergistic combinations of: human mAbs which competitively inhibit, in vitro, the binding of antibodies produced by the cell line 1125H to gpl20, and human mAbs which competitively inhibit, in vitro, the binding of antibodies produced by the cell line 4117C to gpl20, and which are capable of synergistically neutralizing HIV infection. Preferably, the combination is capable of about 95% neutralization of about 1 x 10* infectious units of the MN strain of HIV-1 at a concentration of about 0.5 micrograms/ml. The antibody combination can be used for treatment or prevention of HIV infection. Preferably, the antibodies are used together, but they may be administered sequentially. Also included in the invention is a cell line which produces human monoclonal antibodies specific for the V3 loop of HIV-envelope glycoprotein gpl20, which antibodies have the epitope specificity of those produced by the CP 1 line 4117C to gpl20. The present invention also relates to human monoclonal antibodies specific for a CD-4 binding site epitope of HIV-envelope glycoprotein gpl20 which is conserved among the IIIB, MN, SF-2, and RF HIV-1 strains. The antibodies are capable of neutralizing all of those strains and have high affinity for antigen. Cell lines producing those monoclonal antibodies, as well as related therapeutic and preventive uses, agents, methods of screening using the antibodies, vaccines, and assay kits are included in the invention as well. Brief Description of the Drawings Figure 1 depicts electrophoretic patterns of mAbs 1125H, 2173C, and 2154B.1 reacting with gpl20 and gpl60 on 11% polyacrylamide gels in SDS. Figures 2A - 2C are graphs depicting competition ELISA using a gpl60 coated plate and a CD-4 inhibitor. Figure 3 is a graph depicting the neutralizing activity of mAb 1125H against the MN HIV-1 strain. Figure 4 depicts the apparent affinity of human mAbs 1125H, 2173C, 2154B.1, and 4117C. Figure 5 depicts a hypothetical binding scenario for the 1125H and 4117C antibodies. Figure 6 depicts the synergistic neutralization of the MN strain by human mAbs 1125H and 4117C. Figure 7 depicts the synergistic neutralization of the SF-2 strain by human mAbs 1125H and 4117C. Figures 8a and 8b depict combination index values calculated from experimental curves shown in Figures 6 and 7. Figure 9 depicts results of an experiment measuring the effect of 1125H on binding of 4117C to gpl60 MN and visa versa. Figure 10 depicts the synergistic neutralization of the MN strain by human mAbs 5145A and 4117C. Figure 11 depicts the synergistic neutralization of the SF-2 strain by human mAbs 5145A and 4117C. Figure 12 depicts the synergistic neutralization of the Illb strain by chimp anti- V3 Abs and 1125H. Detailed Description of the Invention We have discovered that when certain antibodies to the anti-CD-4 binding site region and certain antibodies to the anti-V3 region are combined they act synergistically, that is they leutralize HIV at much lower concentrations than those needed for the individual antibodies. Theoretical considerations indicate that the quantities of single Abs required to inhibit virus spread in vivo in infected individuals may be high and not readily obtainable. The enhanced activity of the combination that we have discovered overcomes this problem. To our knowledge, we are the first to observe synergistic neutralization of HIV by a combination of Abs and the first to demonstrate synergistic neutralization of any virus by human mAbs. Further, we have obtained these results for two of the most prevalent HIV strains in the United States, MN and SF-2. We have mathematically analyzed the degree of synergism obtained in these experiments with two of our neutralizing human mAbs: 4117C, an anti-V3 human mAb, and 1125H, an anti-CD-4 binding site human mAb. Results of these analyses indicate that the synergism which we have observed between 1125H and 4117C against HIV^ is as great as any yet seen between any two drugs or reagents, i.e., combination index (CI) values of 0.01-0.2 (Chou 1991) . These two human MAbs, when combined in a 1:1 ratio, neutralize 95-99% of the HIV^ virions at a dose reduction index ranging from 30-150. This means that the same level of neutralization is attained by 30-150 fold less total human mAb when used in combination rather than when either is used alone. The fact that these particular mAbs of the invention are of human origin means that they have distinct advantages for use as an anti-viral drug in humans. These reagents possess a number of advantages over rodent MAbs for this purpose, including increased stability and very low immunogenicity in humans. Thus, human MAbs are much less likely to create deleterious anti-immunoglobulin responses than are mAbs from other species such as rodents, and it should be possible to obtain stable levels of therapeutic doses of human mAbs in humans. Because of the significance of these observations, we have attempted to determine the theoretical mechanism underlying our discovery. Such knowledge might reduce the effort for one skilled in the art to optimize our invention. One mechanism by which the synergism could occur is by enhanced binding of one or both of the Abs to gpl20 in the presence of the other Ab. Using a binding assay wherein recombinant gpl60 (containing the relevant gpl20 epitopes) is immobilized on ELISA plates, we have demonstrated a two-three fold enhancement of binding of the 1125H human mAb to its epitope in the presence of 4117C. In contrast, the binding of 4117C to its epitope is not affected by the presence of 1125H over the same concentration range. Such a unidirectional enhancement of binding has been observed for pairs of mAbs participating in synergistic neutralization of La Crosse (Kingsford 1984) and rubella (Gerna et al. 1987) viruses. Assuming that the enhanced binding of 1125H induced by 4117C occurs on multiple gpl20 molecules on a single virion, it could easily account for the potent synergism observed between 4117C and 1125H in HIV neutralization (Lussenhop 1988) . At this time, our hypothesis for the theory underlying the invention is that the CD-4 binding site becomes more accessible to the 1125H Ab when the 4117C Ab is bound to the V3 loop, whereas the V3 loop is equally accessible to 4117C whether 1125H is bound to the CD-4 binding site or not (Fig. 5) . This model fits with current conceptions of the V3 loop as an accessible, immunodominant epitope cluster and the CD-4 binding site as a less immunogenic, possibly buried, epitope cluster. Furthermore, the model may explain observations on the human humoral immune response to these neutralizing epitopes. Specifically, it has been observed that individuals infected with HIV produce Abs against the V3 loop within a few weeks following infection, whereas antibodies against the CD-4 binding site typically do not appear for months following infection. Our model suggests that the CD-4 binding site may become more immunogenic following the production of anti-V3 Abs in vivo, since the latter's binding to V3 may make the CD- 4 binding site more accessible to the immune system. The invention includes the use of polyclonal antibodies against the CD-4 binding site and V3 regions, as well as the use of human mAbs against these regions. We have demonstrated that chimp polyclonal antibodies against the V3 region also synergize in this manner. An important advantage of the use of human mAbs instead of total serum antibodies for immunotherapy, however, is that the monoclonal antibody technology allows us to produce unlimited amounts of homogeneous reagents. The reagents may be further characterized and studied in detail and used as drugs for passive immunotherapy or treatment of HIV (see further below) . Heterogeneous human serum Abs cannot be used for this purpose; they are available in limited quantities, are different in each individual, and are composed of complex mixtures of antibodies, including blocking and virus-enhancing antibodies. The immortalized cell lines of the invention also allow one to isolate all or a portion of the expressed genes coding for the human mAb. These genes may be altered so as to produce a human mAb with even greater affinity for antigen and/or to change the isotype, idiotype, or effector functions of the human mAb. Expression systems have been developed to allow expression and secretion of genetically engineered human mAbs in mouse cells. Generally, for therapeutic use of human mAbs to be most effective in HIV-infected individuals, the neutralizing human mAb(s) should be extremely potent, so that neutralizing concentrations can be attained in vivo following administration of milligram amounts of human mAb(s) . It has been estimated that between 0.03 to 3 mg/ml of a neutralizing Ab with similar affinity to that of CD-4-gpl20 would be required to eliminate HIV infection in vivo (Layne et al. 1989) . This would necessitate administration of approximately 0.15 to 15 g of Ab per patient, the higher ranges of which are not feasible because of the side-effects associated with administering such high protein doses and the difficulties and cost of producing such large amounts of purified antibodies. The affinity of our human mAb 1125H for gpl20, however, is greater than that of CD-4. The synergism which we have observed makes it possible to greatly reduce the concentration of human mAb. Without wishing to be bound by any theory, we believe that a dose reduction index of at least 1- 2 orders of magnitude (10-100 fold) is achieved using the invention. Thus, the combination of synergistically neutralizing human mAbs of the invention allows more practical application of passive immunotherapy or treatment of HIV-infected individuals. A potential problem with the use of human mAb therapy against HIV is the possible selection of viral mutants escaping neutralization. We believe that the problem is significantly diminished by the combined use of human mAbs according to the invention rather than use of a single human mAb, since two or more independent mutations would then be required to alter both the CD-4 binding site and V-3 loop regions so that they are not recognized by either neutralizing human mAb. The invention includes combinations of human mAbs against the CD-4 binding site region and the V-3 loop region which synergistically neutralize HIV-1. In order to determine which antibodies from these regions synergistically react, human monoclonal antibodies against each of these epitope clusters which have been produced, for example by the methods described below, are screened. A given combination of a human monoclonal antibody against the CD-4 binding site and a human monoclonal antibody against the V-3 region can be screened in a standard neutralization assay for synergistic neutralizing activity by comparing the individual neutralizing activity of each antibody, with the neutralization activity in an assay with the antibodies combined. Examples of such neutralization assays are described below. The ability of the antibody combination to synergize will be evidenced by a significant increase in neutralization activity over that obtained in the presence of equivalent concentrations of the individual antibodies. The extent of synergy can be quantitated by calculating the Combination Index using known statistical methods. For example, a given anti CD-4 binding site human monoclonal antibody can be screened for a significantly increased neutralization activity in combination with the 4117C antibody. Similarly, a given anti V-3 human monoclonal antibody can be screened for synergistic activity by combining it with the 1125H antibody and testing neutralization activity in the same manner. Another manner in which to obtain the synergistic antibodies of the invention is to screen human monoclonal antibodies against the CD- 4 binding site region which competitively inhibit the binding of 1125H to gpl20 in vitro, in combination with either 4117C, or antibodies which competitively inhibit the binding of 4117C to gpl20 in vitro. The antibodies employed in the combination of the invention are directed against the same epitope clusters as 1125H and 4117H. We have determined, however, that human monoclonal antibodies against other epitopes within these specific epitope clusters, i.e. the CD-4 binding site epitope cluster and V-3 loop cluster, also synergistically react. For example, we have found at least one other antibody against the CD-4 binding site which synergistically reacts with 4117C but which is directed at an epitope within the CD-4 binding site cluster different from that of 1125H. This antibody, designated 5145A, is described below. Significant synergistic values within the scope of the invention are, for example, those demonstrated for the results shown in figures 6 and 7. Similarly, combination index values obtained for those results demonstrate significant synergism within the scope of the invention. Combination index values as a a measure of synergism are further discussed below. Preferably the synergistic combination of human mAbs achieves 95% neutralization of about 1 x 10* infectious units of the MN strain of HIV-1 at a concentration of about 0.5 micrograms/ml. In a preferred embodiment of the combination, one of the human mAbs which competitively inhibits the in vitro binding of antibodies produced by the cell line 1125H to gpl20 combines synergistically in neutralizing HIV-1 with other human mAbs competitively inhibit the in vitro binding of antibodies produced by the cell line 4117C to gpl20. In vitro competitive binding assays are well known in the art. Another embodiment of the invention includes a combinati - of human mAbs wherein one of the human mAbs substantially has the epitope specificity of antibodies produced by the cell line 1125H and the other human mAbs substantially have the epitope specificity of antibodies produced by the cell line 4117C. Means of determining epitope specificity are also well known in the art. In another preferred embodiment, one of the human mAbs has the identifying characteristics of those obtained from the cell line 1125H and the other has the identifying characteristics of those obtained from the cell line 4117C. Also included in the invention are transformed cell lines which produce human monoclonal antibodies which have the epitope specificity of those antibodies produced by the cell line 4117C. Human monoclonal antibodies having these specificities are also included in the invention. As noted above, polyclonal antibodies from different sources may be employed, in addition to the human antibodies we have described. Methods have been described in the literature for inducing neutralizing antibodies against different epitopes of HIV gpl20 in both rodents and chimpanzees. Antibodies against the V3 loop have been induced in both rodents (Javaherian et al, 1990) and chimps (Girard et al., 1991) by immunizing animals with synthetic V3 peptides either in free form, or conjugated to KLH. Anti-V3 antibodies have also been induced by immunizing chimps with purified gpl20 and gpl60 (Berman et al., 1990). Antibodies against both regions can also be produced in chimpanzees which have been infected with HIV, although the V3 region is immunodominan , and anti-V3 antibodies will predominate over anti-CD- 4 binding site antibodies. Monoclonal antibodies against these gpl20 epitopes can be prepared from immunized mice by standard techniques, and monoclonal antibodies can be prepared from chimps by following the EBV-transformation procedure described herein for human cells. Specific antibodies against both the V3 region and against the CD-4-binding site can be purified by immunoaffinity chromatography. In one example, AH-Sepharose beads are activated by treatment with glutaraldehyde, and conjugated to either purified V3 peptide or purified gpl20. Antibodies against V3 can be obtained by passing 10-fold diluted hyperimmune serum through the columns to allow the antibodies to bind, and washing off unbound antibodies with saline and 0.5M NaCl solutions. V3-specific antibodies can be eluted from the V3 column by washing with tris-glycine buffer, pH2.7 while V3 specific antibodies can be eluted form the gpl20 column by passing through excess V3 peptide. Antibodies against the CD-4-binding site can be eluted from the gpl20 column with tris- glycine buffer, and then purified by passing over a second gpl20-affinity column in which the CD-4- binding site had been blocked with excess soluble CD-4. Under these conditions, the anti-CD-4 binding site antibodies will not bind to the column and will be found in the flow-through, while all other antibodies will be retained. Following is a description of how human monoclonal antibodies to CD-4 binding site and to the V-3 loop can be obtained. Peripheral blood from HIV-1-seropositive individuals was used to establish transformed clonal human B cell lines which synthesize high affinity human mAbs against HIV-1 envelope proteins. The HIV-1-seropositive donors had normal white blood cell counts and no history of opportunistic infections. Human mAbs obtained against the CD-4 binding sit^ " ere found which are specific for divergent strains of HIV-1, including the IIIB, MN, SF-2 and RF strains. Three cell lines obtained which produce mAbs having this capability are referred to herein as 2173C, 2154B.1 and 1125H. These have been deposited at the ATCC and assigned accession nos. CRL10580, CRL10581, and CRL10582 respectively. Also obtained was a human mAb against the V-3 region, 4117C, which reacts with less strain specificity than prior human antibodies against V- 3. This mAb is specific for a variety of strains, including MN, SF-2 and other strains described below. It has been deposited at the ATCC and assigned accession no. CRL10770. These cultures have been deposited to exemplify the invention, but procedures are described in detail below to allow one skilled in the art to obtain such materials. MAbs from the deposited cell lines can be used to aid in screening to identify cell lines producing mAbs specific for the same, or nearby, epitopes. Using procedures described in detail below, cell lines expressing these mAbs are obtained. The term "neutralizing", where not otherwise defined, is used herein to mean the ability of antibodies, at a concentration no greater than approximately lOOμg/ml, to reduce in vitro infection of H9 cells by at least 90% (compared to control cultures to which no antibody is added) by HIV-1 in the range of 10 4 - 10 5 total infectious units as assessed by the overnight neutralization assay described below. Peripheral blood mononuclear cells from HIV infected individuals were immortalized by transformation with Epstein-Barr virus using a modification described below of the p-. cedure of Gorny et al. (Gorny et al. 1989) . The an i-CD-4 binding site humAb cultures were obtained by screening immortalized cultures for production of anti-env antibody using recombinant gpl60 coated ELISA plates. Our use of recombinantly produced gpl60 in screening differs from other researchers, who have used for example, HIV-l lysate (Gorny et al. 1989) , fixed HIV-1-infected cells (Robinson et al. 1990 AIDS 4:11-19); (Posner et al. 1990), or ConA-immobilized glycoproteins from detergent- disrupted supernatants of HIV-l-infected cells (Robinson et al. 1990 AIDS 4:11-19) to screen cultures. We prefer recombinant gpl60 which is obtained from higher eukaryotic transformed hosts. For example, we used gpl60 expressed by transformed baby hamster kidney cells as per Kieny et al. (Kieny et al. 1988) This version of gpl60, supplied by Pasteur Merieux, lacks the site which is normally cleaved to form gpi20 and gp41. The deletion of this cleavage site, however, is not believed to have any effect on the screening process and to be distant from the epitope[s] which the antibodies of this invention are specific for. Alternative preferred sources include gpl60 or gpl20 obtained from other transformed higher eukaryotic hosts. For example, recombinant gpl20 per Leonard et al. (Leonard et al. 1990) available through the AIDS Research and Reference Reagent Program (NIH) are also believed effective in screening cultures for mAbs of the invention. Competitive ELISAs, testing for competitive inhibition with CD-4 can be performed in order to further screen for cultures producing anti-CD-4 binding site huMabs. Immunofluorescence and neutralization assays may be conducted in order to positively identify those antiCD-4 binding site cultures which are specific for the epitope which affords broad neutralizing activity across the four strains: IIIB, MN, SF-2 and RF, among others. In addition, peptides which present the hvl-V3 loop and peptides which present gp41 epitopes can be used as negative controls to establish the specificity of mAbs for the epitope[s] defined by the anti-CD-4 binding site mAbs of this invention. These peptides are described in greater detail below. Further screening to determine whether cultures are producing mAbs to the same epitope cluster as one of the antibodies of the invention can be done with a competitive ELISA assay using any of the three anti CD-4 binding site antibodies or anti V3 mAbs which we have deposited. Such an assay would determine if mAbs from the culture being screened compete with those described herein in binding to an epitope presented on, for example, recombinant gpl60 coated ELISA plates. MAbs which compete would be specific for the same or adjacent epitopes. A suitable competitive assay is described below. The deposited anti-CD-4 binding site mAbs of this invention do not react with LAV-2. Each of these types of mAbs from our deposited cell lines reacted with both acetone and methanol-fixed HIV- 1 infected cells. Furthermore, each also reacted with formaldehyde-fixed HIV-1 infected cells, a result obtained in our hands only when the epitope recognized is expressed on the infected cells' surface. We have also shown that all three antibodies from our deposited cell lines react with live HIV-1 infected cells. To obtain antibodies against the V-3 region we substituted a peptide consisting of amino acids 305-328 of the MN strain for recombinant gpl60 in screening. That sequence is NYNKRKRIHIGPGRAFYTTKNIIGC, described in Gurgo et al. 1988. 4117C may be characterized by its reactivity with the V3 peptide of the following strains: MN, SF-2, NY-5, CD-451, WMJ-1, WMJ-3, Z- 3, Z-321, and SC; and by its lack of reactivity with the following strains: WMJ-2, LAV-MA, BR, LAV-IIIB, PV-22, ELI, Z-6, NX3-3, JY-1, HXB-2 and MAL. Similarly to the methods described above, competition assays with the deposited antibody 4117C may be carried out to further screen for related antibodies. Examination of the reactivity of antibodies against specific peptides can be used to determine the strain specificity of the screened antibodies. The neutralization abilities of the antibodies deposited have been determined, as described below. It should be appreciated that we used greater amounts of virus in the overnight neutralization assay than other investigators do in their neutralization assays that typically require as long as a week to detect viral infection of control cultures (i.e., those with no antibody added) (Ho et al. 1987) . Therefore, larger amounts of mAb are required to effect a given level of neutralization in our assay than in those assays in which many-fold less virus is added. To compare the efficacy of neutralization by our mAbs with those of other mAbs whose neutralization activity is determined by several- day assays, it is necessary to compare the input number of tissue culture infectious units of virus utilized in the different studies. (A tissue culture infectious unit is approximately equal to two 50% tissue culture infectious doses (TCID) for HIV-1 grown in H9 cells (Harada et al. 1985) . Based on a comparison of this type, and our observation that the 1125H mAb neutralizes the MN (see. Fig. 3) , and IIIB strains with approximately equal efficiency, we estimate that our Mabs neutralize some, if not most, strains of HIV-1 more efficiently than does the N70-1.5e mAb of Robinson et al. (Robinson et al. 1990 Human Ret4roviruses 6:567-579; Ho et al. 1990) or the F105 mAb of Posner et al. (Posner et al. 1990) The 4117C mAb has approximately equal ability to neutralize to MN strain as does 1125H, and appears to neutralize SF-2 even better. These findings are particularly significant as MN and SF-2 are two of the most commonly represented strains in the United States. Experiments were performed to determine which of our antibodies bound at or near the CD-4 binding site of gp 120. This putative site, shown by Lasky ≥t al. (Lasky et al. 1987) and other investigators to include gpl20 amino acids 397- 439 (using the amino acid numbering system for the HTLV-IIIB strain of HIV (Gallo et al. 1984), is relatively conserved across HIV-1 strains. This was tested by conducting an experiment to determine whether soluble CD-4 could inhibit the binding of the mAbs of our deposited cell lines to recombinant gp 160 in a competitive ELISA assay. The results indicated that CD-4 does indeed inhibit binding of the anti CD-4 binding site human mAbs to gpl60 in a concentration-dependent manner. Figure 4 shows the apparent affinity constants of human anti-gp 120 mAbs from the four deposited cell lines described. Antibodies with K-values in the vicinity of 10 9 L/Mole (Berzofsky et al. 1989) are considered to be of high affinity. By this standard, all four human mAbs possess high affinity for gp 120. Further characterization of the anti-CD-4 binding site human mAbs, by way of Western blot analysis using strips prepared with HIV-1 lysate, shows that the epitopes of all 3 of these types of mAbs are destroyed by reduction of disulfide bonds. This indicates that their epitope[s] is dependent on the 3-dimensional conformation of gpl20 and that it is unlikely that linear synthetic antigens which have been created by others (Lasky et al. 1987; Sun et al. 1989) contain the epitopes recognized by our mAbs. Rather, the epitope[s] of these mAbs is probably only recognized upon formation of the appropriate loop or loops by disulfide bonding. Antibody 4117C shows diminished reactivity with reduced gpl20, as compared with unreduced gpl20, but not complete loss of activity. Isotype characterization of the four mAbs of our deposited cell lines was determined by using a variation of the immunofluorescence assay for heavy chain analysis and a variation of ELISA for light chain analysis. The heavy chain isotypes, as determined by immunofluorescence assay, was found to be IgGl. The light chain isotype of the CD-4 binding site antibodies was determined to be Kappa whereas that of the 4117C was determined to be lambda. The procedures are described below. The mAbs of the present invention can be used therapeutically to treat HIV-1 infected individuals. They may be administered by themselves or in conjunction with other anti¬ viral therapies, such as AZT or DDI, in order to slow the progress of HIV-1 induced disease. The synergistic combination which we have discovered is most exciting in this regard as much less of these antibodies is required in order to neutralize HIV. They provide a distinct advantage over the single human antibodies which have been described. In order to administer the synergistic antibodies of the invention, combinations of purified HuMAbs, mixed in appropriate ratios, can be adjusted to 5% solution in sterile saline, yielding a concentration of 50 mg/ml. The best ratio of the synergizing antibodies is determined experimentally, using the 24 hour fluorescent focus assay described below. For example, equipotent concentrations of the two antibodies 1125H and 4117C can be used; i.e. a concentration of each which has been determined to give comparable levels of neutralization to each other. The amount of this solution required for protection can be determined in animal experiments, performed first in Hu-SCID mice (Mosier et al. 1988, McCunc. et al. 1988) and subsequently in chimpanzees. The therapeutic reagent can consist of as few as two synergizing antibodies, although it is believed that the most efficient composition will contain a larger number of different antibodies directed against the two major antigenic sites. This is in order to increase the crossreactivity of the antibodies to different HIV variants which may exist in patients, to inhibit the generation of escape mutants, and to decrease the likelihood of a deleterious anti-idiotype response. It is believed that it may also be beneficial to mix engineered antibodies of different isotypes, including IgGs, IgMs, and IgAs, in order to increase the affinities and effector activities of the antibodies. It is also believed to be beneficial to include antibodies conjugated to toxins, mentioned below, to increase the killing of infected cells, and engineered bispecific antibodies, to increase targeting of infected cells to immune cell-mediated cytotoxic mechanisms. Based on available data and theoretical considerations, a reasonable assumption is that to prevent virus spread in vivo would require achieving plasma concentrations of synergizing neutralizing antibody combinations of 1 to 30 ug/ml. 1-5 mis of the 5% solution (50-250 mg total Ig) is given by intravenous injection to patients. Assuming a total blood volume of 5L, and assuming that all of the delivered Ig remains in the plasma with a half life of 2 weeks, this should result in an initial plasma concentration of the HuMAbs ranging from 10-50 ug/ml. To maintain this level would then require biweekly to bimonthly injections. The treatment is administered to inhibit viral spread, although it m«.y lead to reduction or eradication of virus infection by immunocytoxicity mechanisms after a reasonable period of treatment. Passive administration of human mAbs of the invention may also be used to prevent HIV-1 infection in cases of acute exposure to HIV. As noted above, studies indicate (Devash et al. 1990) a striking correlation between the presence of high affinity serum Abs against the hvl-V3 region of the MN strain in human neonates born to HIV-1 seropositive mothers and the absence of HIV-1 infection in the neonates. Therefore, it can be concluded that the HIV-1 seropositive mother transfers high affinity anti-hvl-v3 antibodies to her fetus, and the fetus is thus protected from HIV-l that it may receive from the mother at the time of birth. The results of Devash are evidence that high affinity neutralizing Ab against HIV-l can protect the fetus from HIV-l infection when present at the time of viral challenge. Hence, the HIV-l neutralizing mAbs of this invention could be passively administered to pregnant seropositive women to prevent their fetuses from becoming HIV-l infected. In addition, these combinations of mAbs may be used to prevent HIV-l infection by administering them to individuals near the time of their exposure to HIV-l. Properties of the preferred mAbs of this invention which make them excellent even by themselves for these applications are: 1) their demonstrated HIV-l neutralizing activity in vitro at low mAb concentrations, 2) their broad HIV-l strain specificity, 3) their high affinity for antigen (HIV-l gp 120) , 4) the fact that they are of human origin and will, therefore, elicit few, if any, deleterious immune reactions whtn administered to humans, and 5) the heavy chain isotype of the mAbs is IgGl, which is significant because human IgGAbs are the only class of Ab able to cross the placenta, and Abs of the IgGl subclass can potentially kill HIV-1-infected cells in vivo via Ab- and complement-dependent cytotoxicity (ACC) and/or Ab-dependent cellular cytotoxicity (ADCC) (see further below) . Although the mAbs of this invention by themselves can be used to prevent HIV-l infection, the mAbs may be modified to enhance their in vivo anti-viral activity by covalent attachment of a toxin such as ricin A or pokeweed antiviral protein to the mAbs. It has been demonstrated that such anti-HIV-1 mAbs-toxins (immunotoxins) are capable of specifically killing HIV-l infected cells in vitro. In considering the use of these Mabs to prevent HIV-l infection, the killing of HIV-l infected cells via ACC, ADCC, or following mAb conjugation with a toxin, could complement the neutralizing activity of our mAbs by eliminating a very small percentage of HIV-l infected cells which might result if 100% neutralization of HIV- 1 by the mAbs is not obtained The anti CD-4 binding site mAbs of this invention can also be used to prepare a vaccine to confer immunity to HIV-l. They may be used to identify the epitope for which they are specific (see below) . Peptides containing that epitope may then be synthesized chemically, using standard Merrifield synthesis techniques, or synthesized by recombinant DNA techniques known in the art. If prepared by recombinant DNA techniques it may be preferred that a higher eukaryotic host be used in order to more closely duplicate glycosylation patterns of the native protein. For example, techniques for recombinant DNA-based synthesis of gpl20 peptides in CHO cells is described by Lasky et al. (Lasky et al. 1986. Alternatively, unglycosylated molecules may be as or more effective than glycosylated molecules; these may be produced by expression of gpl20 peptides from recombinant DNA constructs in bacteria (for example, see Putney et al. 1986) . Once these peptides are chemically synthesized and/or expressed by cells, it is likely that disulfide bonds must be formed between the peptides in order to recreate the epitope (or a similar structure) to be recognized by our anti- CD-4 binding site mAbs. If the peptides are chemically synthesized, disulfide bonds can be formed between the peptides by controlled oxidation following peptide synthesis, whereas peptides expressed in cells are likely to form such bonds between cysteine residues in vivo . In either case, we anticipate that only a fraction of the total molecular species formed would result in a structurefs] recognized by our mAbs. The synthetic or expressed mixture of peptide-derived structures can be passed over an affinity column comprised of covalently bound mAbs in order to identify any molecular species that are recognized by the mAbs. In addition, the entire mixture of peptide-derived structures could be previously radiolabeled in order to determine what percentage of the total mixture is recognized by the mAbs. The bound peptide derived structures(s) can be further characterized by tryptic mapping using HPLC (Leonard et al. 1990) in conjunction with sequencing and amino acid composition analyses. This approach allows one to define the minimal structural requirements of a synthetic and/or recombinant gpl20 fragment that are required for recognition of that fragment by our mAbs.. This is so because a variety of smaller and slightly different synthetic and/or recombinant gpl20 peptide-derived structures can be created once a larger synthetic structure has been defined as a well-recognized epitope (or epitope mimicker) for our mAbs. An alternate method of preparing a vaccine would be to purify chemically (Lasky et al. 1987) or proteolytically fragmented gpl60 on a column having the mAbs of the invention bound thereto. Mixtures of fragments can be obtained which are enriched in the epitope for which the mAbs of the invention are specific. These mixtures, after testing for effectiveness as described above, can be used for immunization. Individual fragments from the mixture may also be isolated and used. Once the epitope has en synthesized or obtained by prepared fragmentation it may be tested for efficacy in rodents and chimpanzees. In such tests, the epitope is presented either alone or covalently attached to a carrier, such as keyhole limpit hemocyanin (KLH) , to enhance its immunogenicity. Adjuvants, such as aluminum hydroxide are also included with the epitope to enhance the immune response. Animals' sera can be tested for the development of broadly neutralizing antibodies, i.e. antibodies capable of neutralizing diverse strains of HIV-l. In the case of chimpanzees, those animals developing such antibodies would then be challenged with different strains of HIV-l and their level of anti-viral protection assessed. Such vaccine trials using recombinant gpl20 and gpl60 in chimpanzees have recently been reported (Berman et al. 1990; Girard et al. 1989) . Although Berman et al. showed that two gpl20-immunized chimpanzees were protected for at least 6 months following challenge with a low dose of virus, only type- specific protection was assessed (challenge with the homologous strain of virus from which the gpl20 was derived) . Using recombinant gpl60 to immunize chimpanzees, Girard, et al. did not observe the development of neutralizing antibodies until the animals were boosted with hvl-V3 , which elicited type-specific protective antibodies in the gpl60-primed animals. The poor elicitation of neutralizing antibodies capable of blocking gpl20- CD-4 binding in both of the studies discussed above indicates that whole gpl20 or gpl60 used as a vaccine will not be effective at eliciting broadly neutralizing antibodies. One of the major reasons for this appears to be that the hvl-V3 region is immunodominant and effectively acts as a v. -y to prevent the immune system from responding to more conserved regions of the molecule, such as the CD-4 binding site. For vaccination purposes, it may therefore be preferable to remove the hvl-V3 region, and possibly other regions, from gpl20 or gpl60 in order to obtain a broadly neutralizing Ab response against the epitope(s) recognized by the anti CD- 4 mAbs of this invention. Thus, peptides synthesized as described above can be engineered using known techniques to delete the hvl-v3 region. Similarly, mixtures of fragments obtained can be further purified to remove fragments containing the hvl-v3 region using known techniques. A vaccine which effectively presents the epitope for which the antibodies of the invention are specific and elicits broad neutralizing ability against HIV-l strains including IIIB, SF2, MN and RF is not known in the art. Such a vaccine would not predominantly produce antibodies against hvl-v3, as we believe ordinarily happens when, for example, whole recombinant gpl20 or gpl60 is used to immunize. By "effectively presents" we mean that the antigen, when used to immunize an uninfected individual, elicits production of antibodies which neutralize the IIIB, SF-2, MN and RF strains, either upon challenge to the individual with those strains or as determined in in-vitro testing. The invention includes a vaccine which incorporates an antigen which consists of an epitope for which the anti CD-4 binding site antibodies of the ivention are specific. The antigen is capable of eliciting an immune response consists essentially of the production of antibodies which have the epitope specificity of the antibodies of the invention. Once a .fragment or construct of gpl20 is obtained which mimics the epitope recognized by our mAbs, the homologous epitope from HIV-2 can be synthesized in order to create a vaccine against HIV-2. The HIV-2 gpl20 sequence is known, and the cysteine residues (which form disulfide bonds) are relatively well conserved between HIV-l and HIV-2 sequences, particularly in the regions around the CD-4 binding site (Myers et al. 1989) . Thus, a vaccine against HIV-2 can be obtained based on the analogous HIV-2 structure to the epitope of HIV-l which we can identify with our mAbs. Another application of the anti CD-4 mAbs in this invention is their use in a competitive immunoassay (see further below) to study the natural human antibody response to the HIV-l epitopes recognized by the mAbs. This type of assay allows research as to : 1) What proportion of HIV-l-infected individuals develop Ab against this epitope[s]? 2) How long after HIV-1- infection and/or at what stage of HIV-1-induced disease does Ab against particular epitopes appear? 3) Do individuals with high titers of Ab against the epitopes have a better prognosis than those without such Ab? 4) Do mothers with Ab against the epitopes transmit HIV-l to their fetus less frequently than those mothers without Ab against this epitope? Once these studies have been done, correlations may appear between the presence or absence of such Abs and stage of HIV- 1 infection, prognosis for HIV-1-infected individuals, or indications for intervention. In these cases, the competitive immunoassay discussed above could be used as a diagnostic assay to determine specific parameters of HIV-l infection. Thus, the present invention also includes test kits to measure th^ r resence of human Abs against the epitopes of th-_ nti CD-4 mAbs claimed in this application. The kits contain human monoclonal antibodies having the specificity described above, a solid phase on which is coated an antigen which the monoclonal antibodies are specific for, and means for detecting the formation of a complex between the monoclonal antibodies and the antigen. A competitive ELISA using biotin labeled human mAbs can be performed similarly to the competitive inhibition assay described below. Such an assay determines whether the sample has any antibody competing with the antibody of the invention. An assay for determining the presence of the antigen which the mAbs of the invention bind to can also be performed using, for example, a sandwich format wherein a solid phase is coated with antibody to HIV envelope, the sample is added, and then biotin labeled mAb of the invention is added. Following a wash, enzyme labeled avidin would then be added as well as enzyme substrate. Such general types of assays are well known in the art. The invention also includes kits for determining an antigen for which the anti CD-4 mAbs of the invention are specific. For example such a kit may comprise the anti CD-4 mAbs of the invention, a solid phase on which is coated an antibody specific for HIV-l env, and means for detecting the formation of a complex among the mAbs of the invention, the antibody specific for HIV-l env, and an HIV antigen for which the mAbs are specific. The practice of such a sandwich type immunoassay is well known to one skilled in the art. Gram quantities of this invention's mAbs are preferably obtained in order to administer efficacious amounts of these .^agents to humans in-vivo . These amounts coul ' be obtained by growth of our human cell lines in a ini- bioreactor. Additionally, cost-effective methods to increase human mAb production are: 1) fusion of our EBV-transformed lines with a human/mouse heteromyeloma (Teng et al. 1983; Kazbor et al. 1982) and 2) PCR amplification of expressed i munoglobulin V H and V L genes from human cell lines using published human primer sequences (Larrick et al. 1989) , followed by cloning of these genes into available eukaryotic expression vectors containing human constant region genes (Orlandi et al. 1989) . Alternatively the genes could be directly cloned from cDNAs or genomic DNA of the antibody producing human or non-human cells. The latter constructs are then expressed as mAbs at high levels in mouse myeloma cell lines. Transformed cell lines producing recombinant monoclonal antibodies are included within the scope of the invention, as are the antibodies produced thereby. The invention also includes moieties having the same function as monoclonal antibodies, such as Fab fragments, F(ab') 2 , Fd or other fragments, modified proteins such as chimeras with altered Fc regions, or having mutagenized idiotypic regions, so long as they bind to the same epitope as the human monoclonal antibodies of the invention. Techniques for producing such fragments or modified antibodies are known to one skilled in the art (Parham 1986) . Previous studies have shown that the affinities of huMabs to their antigens, and the abilities of these antibodies to neutralize infectious agents can be significantly enhanced by changing their isotypes. For example, - human IgG mAb against group B streptococci was converted to an IgM by standard recombinant DNA methods (Shuford et al. 1991). The IgM form of the antibody showed an approximately 100-fold greater level of binding in an ELISA assay than the IgG, and was able to prevent mice from lethal effects of the bacteria at a greater than 16 fold reduction in concentration. Significant enhancement of the neutralizing activity of antibodies described herein against either the V3 or antiCD-4 epitope clusters can be expected to be achieved by changing their isotypes. It is believed that the preferred therapeutic reagent of this invention consists of mixtures of engineered antibodies of different isotypes, including IgGs, IgMs, and IgAs, in order to increase the affinities and effector activities of the antibodies. The present invention is further described herein below. These examples are for illustration and are not intended to limit the invention. Examples Peripheral blood from HIV-l seropositive individuals who are hemophiliacs was obtained. These individuals were classified as Walter Reed 5 Stage 2A, i.e., they had normal white blood cell counts and no history of opportunistic infections. Preparation and screening of cell lines producing human mAbs according to this invention Peripheral blood mononuclear cells were 10 isolated by centrifugation of fresh, heparinized blood, diluted 1:3 with RPMI1640 medium (Flow®), on Histopaque (Sigma®) at 400 x g for 30 min. .. room temperature. Cells at the medium/Histopaque interface were recovered and diluted 7-8 fold with 15 RPMI 1640 medium. The cells were spun down (400 x g, 20 min.), and then resuspended in 50 ml of RPMI 1640 medium, counted, and spun down again as before. Cells were then resuspended at a density of 2 x 10 6 cells/ml in RPMI 1640 medium 20 supplemented with 15% (vol/vol) fetal calf serum (HyClone®) , 2 mM L-glutamine, penicillin (50 units/ml) , and streptomycin (50μg/ml) (complete medium) . Epstein-Barr virus (EBV) 100X stock, (Raubitschek et al. 1985) was then added so that 25 it constituted 1/10 of the final volume of the cell suspension, and the cells were incubated * overnight at 37°C in 5% C0 2 in a 25 cm 2 flask. The following day, the cells were gently resuspended, * diluted approximately 10-fold with RPMI 1640 30 medium, and spun down. The pellet was resuspended at a final density of 10 4 cells/ml in complete medium. The cells were then plated in U bottom 96-well plates at lOOμl (1000 cells) per well onto lOOμl of irradiated (3500 rads) rat embryo fibroblasts in complete medium. The cultures were fed weekly for 4 weeks at which time approximately 45% of the wells exhibited growth. Then their supernatants were assayed for anti-env Ab production (see below) . Those cultures testing positive were picked onto fresh irradiated rat embryo fibroblasts in 96-well plates and re- assayed the following week. Cultures remaining positive were then sublined onto irradiated rat embryo fibroblasts at densities ranging from 1 to 100 cells/well. Those cultures growing in plates in which the number of wells with growth indicated > 95% probability of monoclonality as determined by the Poisson distribution (Coller et al. 1987) were re-tested for anti-envelope antibody production, and those testing positive were expanded into bulk culture. In this way we obtained cell lines 1125H, 2154B.1, 2173C and 4117C. The monoclonality of these cultures was confirmed by Southern blot analysis using an immunoglobulin J H gene probe. Southern blot analysis to determine clonality of cell lines. DNA was isolated from the four identified cell lines followed by restriction enzyme digestion, agarose gel electrophoresis, blotting to nitrocellulose, and hybridization to 3z P-labeled nick-translated probe. (Eckhardt et al. 1982) . The DNA was cut with Hind III, which allows visualization of rearrangements due to V-D-J joining upon hybridization with an immunoglobulin J H region probe (Ravetch et al. 1981) . The J H probe used was a EcoRI-Hindlll fragment approximately 3.3 kilobases in length from the germ line J H locus; the Hindlll site at its 3' end is present in the germ line DNA [Ravetch, J. V., U. Siebenlist, S. Korsmeyer, T. Waldmann, and P. Leder. (1981) Cell 27:583-591], whereas the EcoRI site at its 5' end was created upon cloning. The monoclonality of the four cell lines was confirmed. Methods Used for Detection of Human Anti-gpl20 mAbs Produced by Human Cell Lines ELISA assays were used to detect HIV env- specific Abs. The initial screening of EBV- transformed human cultures for production of anti- env Ab was done using either recombinant gpl60 (Kieny et al.) or V3 MN peptide to coat PVC ELISA plates (Flow/ICN) . In later assays on supernatants from cultures identified as positive in the initial screening, a variety of other HIV proteins or peptides can be used to determine the specificity of the human mAbs. These include recombinant gpl20 of the IIIB strain produced by Celltech, Inc. and available through the AIDS Research and Reference Reagent Program (NIH) or described by (Leonard et al. 1990) synthetic V3 peptides from a variety of strains (strain specificity is described above) ; or pl21, a gp41 peptide (amino acids 565-646) sold commercially by Dupont or described in Chang, et al., European Patent Application 0199438 published October 29, 1986. 4117C is negative for gpl20 of the IIIB strain and for pl21. 1125H is negative for the V3 peptides, and for the gp41 peptide as well. Unless noted otherwise, 50 ng/well of protein diluted in Na 2 C0 3 /NaHC0 3 buffer, pH 9.8 was incubated in the plates overnight at 4°C. The following day, the plate was washed 3 times with PBS/tweenyazide (Sigma® PBS with 0.05% Tween 20, 1 mM NaN 3 ) . Next, the wells of the plate were blocked (to prevent nonspecific binding) by incubation with 50μl of 2% BSA in PBS for 1.5 hr., 37° C. After washing as before, 50μl of supernatant from human cell lines was added to the wells and incubated for 1.5 hr., 37 C C. Unbound Ab was washed from the wells, and 50μl of a 1/500 dilution of goat anti-human IgG conjugated to alkaline phosphatase (Zymed®) in 2% BSA was added to each well. After an incubation and wash identical to those discussed above, 50μl of alkaline phosphatase substrate (disodium p-nitrophenyl phosphate) , 1 mg/ml in diethanolamine buffer (1M diethanolamine, 0.5mM MgCl 2 , 3mM NaN 3 , pH 9.8) was added. The absorbance at 405nm was read in a Titertek Multiskan Plus® ELISA reader (Flow®) at times ranging from 5 min. to 2 hr. following substrate addition. The background obtained when culture media was used rather than supernatant from human cell lines was automatically subtracted from the results by the ELISA reader. Radioimmunoprecipitation and Western Blot Assays. For radioimmunoprecipitation assays, glycoproteins in HIV-1-infected cells at 5-7 x 10 s cells/ml were labeled with 3 H-glucosamine (lOOμ Ci/ml) as described (Pinter et al. 1989) . The cells were then lysed and immunoprecipitated as previously described (Pinter et al. 1988) . Briefly, the cell pellet was brought up in lysis buffer at a concentration of 5 x 10 6 cells per ml. The lysate was then precleared with fixed, killed staphylococcus aureus cells (Staph A) , and 70μl of pre-cleared lysate was added to 70μl of supernatant from human Ab-producing cell lines or 1/400 dilution of human sera. Following an incubation and precipitation by Staph A, the pellet was brought up in Laemmli sample buffer containing 1% DTT and run on an 11% polyacrylamide gel as described (Laemmli 1970) . Fluorography (Bonner et al 1974) then allowed detection of radiolabeled, immunoprecipitated glycoproteins in 5 the gel. Western blot analysis was performed using strips prepared with HIV-l lysate essentially as described (Pinter et al. 1989) . The lysate was diluted in buffer composed of 0.01M Tris 10 hydrochloride (pH 7.4) ,10% glycerol, 0.01% bromophenol blue, either 0 or 1% DTT, and 1% SDS. The Western blot strips were incubated with a 1/2 dilution of supernatant from human Ab-producing cell lines or a 1/100 dilution of human serum, and 15 bound Ab was detected as described (Pinter et al 1989) . HIV Strains HIV-l strains IIIB (Popovic et al. 1984; Ratner et al. 1985) and SF2 (Levy et al. 1984; 20 Sanchez-Pescador et al. 1985) were obtained from Dr. Jeffrey Laurence, Cornell University School of Medicine; strains MN (Gallo et al. 1984; Shaw et al. 1984) and RF (Popovic et al. 1984; Starcich et al. 1986) were obtained from the NIH AIDS Research 25 and Reagent Repository. The identities of strains IIIB, MN, and RF were confirmed by us using strain-specific antisera against the hypervariable V3 loop (hvl-v3) of each strain in an immunofluorescence assay. The IIIB-specific 30 chimpanzee antiserum was obtained through a J- collaboration with Dr. Marc Girard, Pasteur Institute, whereas the MN- and RF-specific rabbit antisera were generously provided by Dr. Robert Neurath, New York Blood Center. An HIV-2 strain, 35 LAV-2 (Clavel et al. 1986) was obtained from Dr. Alvin Friedman-Kien, New York University School of Medicine, with permission from Luc Montagnier, Pasteur Institute. Immunofluorescence Assays for HIV Strain Specificity of mAbs Prior to attachment of cells to Multi-spot microscope slides (Shandon) for immunofluorescence analysis, the slides were treated with poly-L- lysine (lOOμg/ml in PBS, 50ml per well) for 30 min at room temperature. The slides were then washed with distilled water and dried. Cells that were 100% HIV-1-infected or uninfected were then washed in steriλ"- PBS, resuspended in PBS at a density of 1-2 x 10 6 cells/ml, and incubated on the poly-L lysine-coated slides (50μl cell suspension/well) at 37 β C for 30 min.. The slides were then washed 2X in 100-200 ml PBS, using a slide-holder and trays. For formaldehyde fixation, 0.5% formaldehyde in PBS containing lOmM NaN 3 was then added to each well of the slides and incubated with the immobilized cells for 30 min. at room temperature. The slides were then washed IX in distilled H 2 0 as discussed above and allowed to dry. For acetone or methanol fixation, following the 2 washes in PBS discussed above, the slides were washed IX in distilled water and then incubated in 100-200 ml of acetone or methanol for 8 mins. The slides were then removed from the fixative and allowed to air dry. Prior to addition of human Abs to the fixed cells on slides, non-specific binding was blocked by incubation of the slides with 1 mg/ml bovine gamma globulin in PBS for 30 min. at 37 C C. After washing 2 times in PBS and once in distilled H 2 0, the slides were allowed to air dry. Undiluted supernatant from human Ab- producing cell lines or serum diluted 1/100 to 1/200 in 1 mg/ml bovine gamma globulin in PBS was then incubated at 25-50μl well for 1 hr. at 37°C with the fixed cells on the slides. After washing and drying the 5 slides as discussed above, a 1/50 dilution of goat » anti-human IgG conjugated to FITC (Zymed) in 1 mg/ml bovine gamma globulin in PBS was incubated with the slides as in the previous step. After washing and air drying the slides as discussed 10 above, the cells on the slides were counterstained with 0.05% Evans Blue for 10 min. at room temperature. The slides were then washed extensively with distilled H 2 0 and air dried. Finally 2μl per well of 0.033M DTT in 50% glycerol 15 in PBS was added as preservative, a coverslip was placed over the wells, and the slides were viewed under a Nikon Diaphot immunofluorescence microscope. 20 Determination of mAb Isotypes Heavy chain subclass was determined using a variation of the immunofluorescence assay. Human mAb-producing cells were attached to slides and fixed with acetone. The slides were blocked with 25 bovine gamma globulin and washed as discussed above. Next, a 1/5000 dilution of human IgG subclass-specific mouse monoclonal Ab (Zymed) (specifically, anti-IgGl and anti-IgG2 were used in these experiments) was added and incubated for * 30 1 hr. at 37° C. Following washing and drying of the slides, biotinylated goat anti ouse IgG * (Zymed) , 1/200 dilution, was added and incubated for 1 hr. , 37° C. After washing and drying the slides, a 1/50 dilution of FITC/streptavidin 35 (Zymed) , was added and incubated for 1 hr. , 37 C C. After washing and drying the slides, the cells were counterstained, and viewed as discussed above. Light chain isotype was determined by a variation of the ELISA assay discussed above. Following incubation of supernatant from mAb- producing human cells with gpl60 in duplicate ELISA wells, the mAb isotype was determined by development of one well with goat anti-human kappa Ab conjugated to alkaline phosphatase and the other well with goat anti-human lambda Ab conjugated to alkaline phosphatase. Both of the latter reagents (Tago) were used at 1/3250 dilution. . L mZC Competitive Inhibition Assays These assays were done using a variation of the ELISA procedure discussed above. ELISA plates were coated with gp 160, blocked with BSA, and washed. In the CD-4 inhibition experiments, a constant volume of supernatant from human Ab- producing cells was added to varying amounts of soluble CD-4 (in PBS) in eppendorf tubes, and RPMI was then added to yield a constant total volume. After mixing, the supernatant/CD-4 mixtures were pipetted at 50μl/well into the ELISA plates. The remainder of the ELISA procedure was carried out as discussed above. Neutralization Assay Prior to conducting neutralization assays, the human mAbs were purified on recombinant protein A Sepharose columns essentially as described (Harlow et al. 1988) . The column fractions containing mAb (as determined by ELISA assay of fraction aliquots) were concentrated in an AMICON centriprep 30 column and dialyzed against PBS. An irrelevant mAb of the IgG2 subclass was purified in the same manner from the 1A2 cell line (Siadek et al. 1985), which was derived from the GM1500 cell line (Dolby et al. 1980) . The purified 1A2 mAb was used as a negative control in neutralization and competitive inhibition experiments. The neutralization assay was carried out as follows. Purified Abs, or combinations of Abs, were diluted in complete media containing 10% FCS to obtain concentrations ranging from 0.1 to 20 μg/ml in a total volume of lOOμl. Included in this volume was approximately 10 4 -10 s tissue culture iv " 'tious units of HIV-l. After a 30 min. prein&l.oation of virus and mAb at room temperature, the mixtures were each added to 1 x 10 5 H9 cells in a final volume of 200 μl. Following an overnight incubation at 37° C, the cells in each well were plated onto separate wells of poly L-lysine-coated slides and stained sequentially with a rat anti-nef serum (1/200) followed by a rabbit anti-rat IgG Ab conjugated to FITC (1/50) (Zymed) . The latter two antibodies were diluted in 1 mg/ml bovine gamma globulin in PBS. The cells were counterstained with Evan's Blue, and the percentage of infected cells from each culture relative to the control (no mAb added) was assessed by counting immunofluorescent cells versus total counterstained cells under the fluorescence microscope. Specificity of mAbs The specificity of 1125H, 2173C and 2154B.1 for gpl20 was determined by ELISA reactivity of supernatants with recombinant gpl20 as well as by radioimmunoprecipitation/SDS gel analysis using HIV-l infected cell lysates. Figure 1 shows the results. In the left panel (lanes 1-5), lysate from H9 cells infected with the IIIB strain was used, whereas in the right panel (lanes 6-10) , lysate from H9 cells infected with the RF strain was used. These lysates were immunoprecipitated with: a 1/400 dilution of human serum from an HIV- 1 seropositive individual (lanes 1 & 6); 0.7 μg purified 1125H mAb (lanes 2 & 7) ; undiluted supernatant from 1125H (lanes 3 & 8) , 2154B.1 (lanes 4 & 9) , and 2173C (lanes 5 & 10) cells. The latter three supernatants contained approximately 1-3 μg mAb/ml. Results with t s "uman serum (lane 1, positive control) show that ' : ..e expected IIIB strain glycoproteins, gpl60 iPr t . v , precursor envelope protein) , gpl20 (S_7,- v , surface envelope protein) , and gp41 iTM. nv , transmembrane envelope protein) are immunoprecitated. The corresponding glycoproteins of the RF strain (lane 6) each migrate at a lower apparent molecular weight than their counterparts from the IIIB strain (lane 1) . This must be due to glycosylation differences in the RF and IIIB strain glycoproteins, since there is no significant difference in the number of amino acids in these molecules between RF and IIIB strains (Starcich et al. 1986) . Since the names gpl60, gpl20, and gp41 given to the IIIB strain- related isolates of HIV-l are only appropriate to glycoproteins migrating at the apparent molecular weights of 160, 120, and 41 kilodaltons, we have chosen to use the more appropriate names of PR, nv , Sϋ,. v l and TM- nv _ which imply a specific protein structure and function for these molecules rather than an apparent molecular weight. Results with our mAbs (lanes 2-5 & 7-10) demonstrate that they are specific for SU- nv (gpl20 of IIIB strain) , reacting only with the PJ.. nv , which contains the _?D. nv sequences, and the Sϋ-„ v itself, but not with the TM. nv (gp41 of IIIB strain) . Furthermore, the 5 mAbs recognize both the RF and IIIB strain Sϋ, nv * molecules. Thus these human mAbs are highly specific for gpl20 and reactivity with both IIIB and RF glycoproteins is shown. The 4117C humAb is specific for gpl20 as 10 determined by ELISA and Western blot analyses. Strain Specificity The strain specificity of the 1125H, 2173C, 2154B.1 and 4117C mAbs was test. d by immunofluorescence assay usi ..--. __ixed cells 15 infected with one of several HIV strains. The anti-CD-4 mAbs were reactive with the IIIB, MN, SF-2 and RF HIV-l strains, as well as with one (JRCSF) of two primary HIV isolates tested. None of these mAbs reacted with LAV-2, an 20 HIV-2 isolate. Each of the three mAbs reacted with both acetone- and methanol-fixed HIV-infected cells. Furthermore, each of the mAbs reacted with formaldehyde-fixed HIV-1-infected cells, a result obtained in applicant's hands only when the 25 epitope recognized by the mAb is expressed at the cell surface. Each of the mAbs also reacted with live, HIV-1-infected cells. The 4117 mAb was reactive with the MN, SF-2, * and the JRCSF primary isolate, as well as with two 30 strains known as FV and 11699, but not with the * ■ IIIB and RF strains. CD-4 Competition To test whether the epitope recognized by the 1125H, 2173C and 2154B.1 mAbs is in or near the CD-4 binding site of gp 120, the ability of soluble CD-4 to inhibit the binding of applicant's mAbs to recombinant gp 160 in a competitive ELISA assay was examined. The results are shown in figure 2. In figure 2A the open squares represent supernatant from 50- 69, an anti-gp41 human mAb (Gorny et al. 1989) . The closed diamonds in figure 2A represent supernatant from 1125H. Figure 2B shows results for supernatant from 2173C. Figure 2C shows results for supernatant from 2154B.1. ""..e results show that the binding of the 50-69 (co....rol mAb) to gpl60 is not inhibited by soluble CD-4, whereas that of the other three mAbs (1125H, 2173C, 2154B.1) is inhibited by soluble CD-4 in a concentration-dependent fashion. The differences in absorbance observed for the four human mAbs in the absence of soluble CD-4 are due to differences in the absolute concentrations and/or affinities of the mAbs in the supernatants tested. Taking the concentration of mAb in each of the experiments into account, CD-4 inhibited each of the mAbs' binding to gpl60 to approximately the same extent. These results indicate that: a) the epitope(s) recognized by these mAbs is in or near the CD-4 binding site or b) CD-4 binding to gp 160 creates a conformational change in the latter which causes the epitope(s) of the mAbs to become inaccessible. We believe, based on studies of the binding of this antibody to site specific mutants of gpl20 that the epitope is in fact part of the CD-4 binding site. Affinities of mAbs The affinity of mAbs for gpl60 or V3„ N was determined by diluting mAbs of known concentration and assaying the various dilutions on gpl60 or V3„ N coated plates by ELISA as discussed above. It has been demonstrated that the concentration at which half-maximal Ab binding is observed is a rough value of 1/K (van Heyningen et al. 1987) . Results of these measurements are shown in Table 1. Antibodies with K values in the vicinity of 10 9 L/mole are considered to be of high affinity Berzofsky et al. 1989) by this criterion, all four of our mAbs possess high affinity for gpl20. Chain Isotypes The heavy chain isotype of each of the 1125H, 2173C, 2154B.1 and 4117C mAbs was determined to be IgGl. The light chain isotype of each of the three antiCD-4 binding site mAbs was determined to be kappa whereas that of 4117C was found to be lambda. These results were obtained as described above. Neutralization Abilities The results of the in vitro neutralization assays indicate that human mAbs 1125H, 2173C and 2154B.1 have potent neutralizing abilities against HIV-l strains: IIIB, MN, SF-2 and RF. The potent neutralizing activity of 1125H against the MN strain is shown in Figure 3. Human mAb 4117C had potent neutralization against the MN and SF-2 strains, as shown in Figures 6 and 7 respectively. Destruction of the gpl20 epitope of mAbs 1125H, 2173C and 2154B.1 upon reduction Western blot analysis of 1125H mAb on reduced or non-reduced HIV-l lysate was performed as described above. On the non-reduced lysate strip, bands at 120 kD were observed (data not shown) , while on the reduced strip, no reaction of the mAbs with the HIV-l lysate was seen. These results indicate that the epitope(s) of the mAbs is destroyed by reduction of disulfide bonds. Quantitation of human mAbs These determinations were made by ELISA using goat anti-human IgG (Zymed) (lOμg/ml in 1% BSA in PBS) to coat the plates and to capture the human Ab in supernatants or purified Ab preparations Gorny et al. 1989) . The bound human Ab was detected with goat anti-human IgG conjugated to alkaline phosphatase (Zymed) , and a standard curve was produced for each assay using affinity- purified human IgG (Cappel) of known concentration. Competition Assay for Screening Culture Supernatants or Human Serum A competition assay can be performed in order to screen culture supernatants or human serum for antibody against the epitopes, or epitope clusters, which the mAbs of the invention are specific for. The competition assay is carried out essentially as described above for the competition assay with CD-4. However, biotin- labeled mAbs from cell line 1125H, 2173C, 2154B.1 or 4117C are used in competition with supernatant from the culture screened to bind to gpl60 or V3„ N * coated ELISA wells. Binding of the biotin labeled mAb is detected by a subsequent incubation with % 5 alkaline phosphatase-conjugated streptavidin. Normal human serum or supernatant containing human IgG not specific for the epitope are used as negative controls. Specificity of anti-V3 antibody 4117C 10 4117C was found to recognize a variety of divergent HIV strains, including MN, SF-2, FV (New York) , 11699 (Central Africa) , and the JR-CSF primary isolate (Los Angeles) (Koyanagi et al. 1987) . 4117C human mAb is less strain specific 15 than other anti-V3 human mAbs that have been described (Scott et al. 1990, Zolla-Pazner et al. 1990 ) . Comparison of the V3 sequences of the isolates recognized by 4117C reveals that the sequence GPGR at the tip of the loop is shared by 20 all of them. In addition, the sequence IXI just to the left of the GPGR is highly conserved among these isolates. These observations indicate that 4117C may be directed against a relatively conserved sequence near the tip of the loop. The 25 GPGRAF sequence at the tip of the loop has recently been shown to induce broadly reactive anti-V3 Abs in experimental animals (Javaherian et al. 1990) . Figs. 6 and 7 show that human mAb 4117C exhibits potent neutralizing activity 30 against the MN and SF-2 strains of HIV, respectively. Synergistic neutralization of HIV by human mAbs 1125H and 4117C. An exciting new discovery is that certain antibodies against the CD-4 binding site and certain antibodies against the V-3 loop synergize to neutralize HIV. 1125H human mAb against the CD-4 binding site synergizes with our 4117C human mAb against the V3 loop to neutralize HIV. Fig. 6 shows that an equimolar mixture of the two human mAbs neutralizes the MN strain of HIV significantly better than either of the two human mAbs alone. The mixture of human mAbs effects 50% neutralization of virus at approximately a 5 fold lower concentration than that of either human mAb alone, meaning that each of the individual human mAbs is 10 fold more effective when mixed with the other human mAb than when used alone. This is a dose reduction index of 10 for each of the human mAbs at the 50% neutralization level. When higher, more physiologically significant, levels of neutralization are examined, the synergistic effect is even more dramatic. Mathematical analysis of the results shown in Fig. 6 indicates that at 95% neutralization, dose reduction indices of 57 and 29 are obtained for 1125H and 4117C, respectively, whereas at 99% neutralization, dose reduction indices of 156 and 54 are obtained for these human mAbs. We have also demonstrated synergistic neutralization of the SF-2 strain of HIV by human mAbs 1125H and 4117C (Fig. 7) . The results are impressive though not as profound as those seen with the MN strain. This is probably due to the fact that neither of the human mAbs individually has as great a neutralizing activity for the SF-2 strain as for the MN strain. The dose reduction indices for 50% neutralization of SF-2 are 9 and 4 for 1125H and 4117C, respectively, whereas those at 95% neutralization are 57 and 9 for these human mAbs. We have analyzed the degree of synergism - 5 between 1125H and 4117C. The results indicate that the synergism which we have observed against the MN strain is as great as any yet seen between any two drugs or antibodies, i.e., +4 synergism, whereas that against the SF-2 strain is a +3 10 synergism, on a scale of +1 to +4 (Chou 1991) . These values are assigned based on the combination index (CI) values calculated from experimental curves such as those shown in Figs. 6 and 7. CI values less than 1 indicate synergy (Chou and 15 -falalay 1984) . Fig. 8 shows the CI plots calculated from our experimental results (Figs. 6 and 7) . CI is plotted versus F., where F. x 100 = the % neutralization observed, i.e. Fa = %neutralization/100. Calculation of combination 20 index values is well known in the art. In order to address the mechanism of this synergistic neutralization, the effect of 4117C on the binding of 1125H to its gpl20 epitope and vice versa has been evaluated. To carry out these 25 experiments, one of the human mAbs was tagged with biotin, and mixed with different amounts of the second, unlabeled antibody. Bound biotinylated antibodies were then detected by the binding of streptavidin in an ELISA assay. The antigen used 30 was recombinant gpl60 of the MN strain that contains the relevant gpl20 epitopes bound by both of the human mAbs. We have consistently been able to observe a 2-3 fold increase in 1125H-biotin binding to gpl60„ N in the presence an equimolar 35 concentration of 4117C, whereas 4117C-biotin binding to gpl60 MN appears to be unaffected by 1125H (Fig. 9) . Our working hypothesis based on these results has been presented in Fig. 5. Derivation and characteristics of a new HuMAb against the CD-4 binding site, 5145A Cell line 5145A was derived by the same protocol as 1125H. The 5145A HuMAb has the following characteristics. Its binding to gpl60 is inhibited by soluble CD-4 similarly to that of 1125H, and its epitope is destroyed by reduction, also similar to that of 1125H. Its apparent affinity constant is 1 x 10 9 L/mole. It is an IgG HuMAb; its IgG subclass remains to be determined. Its light chain is of the kappa isotype. Like 1125H, 5145A reacts with MN-, IIIB- and RF- infected cells by immunofluorescence. However, 5145A recognizes a different epitope of the CD-4 binding site than 1125H based on its neutralization of the 4 HIV-l strains mentioned above. Specifically, 1125H neutralizes the IIIB, SF-2, and MN strains significantly better than the RF and SF-2 strains, whereas the 5145A HuMAb exhibits virtually identical neutralization of the 4 strains discussed and at levels comparable to the 1125H HuMAb's neutralization of the MN strain (see Fig. 6) . This difference in pattern of strain neutralization must be due to a difference in epitope specificity of the 5145A and 1125H HuMAbs, since posses comparable affinity for gpl20. Synergistic neutralization of the MN and SF-2 strains of HIV-l by 5145A and 4117C. Used at a 1:1 molar ratio, HuMAbs 5145A (anti-CD binding site) and 4117C (anti-V3) synergistically neutralize MN and SF-2 strains, as seen in Figs. 10 and 11, respectively. This demonstrates that anti-CD-4 binding site HuMAbs of differing epitope specificities (1125H and 5145A) can participate in synergistic neutralization with an antibody against the V3 loop. Isolation and characterization of chimpanzee anti-V3 Abs from serum of an animal hyperimmunized with V3 peptide Chimpanzee #499 was immunized with V3 peptide as described in Girard et al. 1991 (PNAS paper) and serum taken at the peak of neutralizing Ab titer (also shown in op. cit.). The anti-V3 Abs were purified on an affinity column with V3 peptide of IIIB strain attached as described below. The chimpanzee Ab concentration was determined as described for the HuMAbs, except that the IgM, IgA, and IgG concentrations were determined in separate assays with purified human Ab standards of each isotope. The total chimpanzee anti-V3 Ab concentration was taken to be the sum of the concentrations of these three antibody classes. We have shown that this chimpanzee anti-V3 Ab's binding to the V3 loop is destroyed by spontaneous proteolytic cleavage of V3 (Tilley et al. 1991, Res. Virol, in press) , indicating that its epitope is on the right (C- terminal) side of the loop near the tip. In contrast, we believe that our anti-V3 HuMAb, 4117C is directed toward an epitope overlapping the tip of the loop. The assignation of these epitopes correlates with the observation that the chimpanzee anti-V3 Abs are strain-specific (Girard et al. 1991, PNAS), whereas our anti-V3 HuMAl 4117C recognizes a variety of divergent HIV-l strains, i.e., is against a conserved epitope involving the tip of the loop. Synergistic neutralization of the IIIB strain of HIV-l by anti-V3 chimp Abs and 1125H (anti-CD-4 binding site HuMAb) Figure 12 shows that chimp anti-V3 Abs and 1125H mixed at 1:1 molar ratio synergistically neutralize the Illb strain. This is significant not only because it shows that anti-V3 Abs against different epitopes can participate in synergistic neutralization (chimp anti-V3 and 4117C) , but also because it includes another HIV-l strain, i.e., IIIB, in our observations of synergistic p.- .....-alization. List of References * * Anderson, L.J. , Bingham, P. , and Hierholzer, J.D. (1988) . Neutralization of respiratory -*, syncytial virus by individual and mixtures of F 5 and G protein monoclonal antibodies. J. Virol. 62, 4232-4238. Berman, P.W. , T.J. Gregory, L. Riddle, G.R. Nakamura, M.A. Champe, J.P. Porter, F.M. Wurm, R.D. Hershberg, E.K. Cobb, and J.W. Eichberg. 10 (1990) Nature 345:622-625. Berman, P.W., Riddle, L. , Nakamura, G., Haffar, O.K., Nunes, W.M. , Skehel, P., Byrn, R. , Groopman, J. , Matthrews, T. , and Gregory, T. (1989) . Ξ.i-session and immunogenicity of the 15 extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gpl60. J. Virol. 63, 3489-3498. Berman, P.W., Gregory, T.J., Riddle, L. , Nakamura, G.R., Champe, M.A. , Porter, J.P., Wurm, 20 F.M. , Hershberg, R.D., Cobb, E.K., and Eichberg, J.W. (1990) . Protection of chimpanzees from infection by HIV-l after vaccination with recombinant glycoprotein gpl20 but not gpl60. Nature. 345, 622-625. 25 Berzofsky, J. A., S. L. Epstein, and I. J. Berkower. (1989) in Fundamental Immunology, Second Edition, W.E. Paul (ed.). Raven Press, Ltd., New York, p. 315-356. Bonner, W. M. , and R. A. Laskey. (1974) Eur. 30 J. Biochem. 46:83-88. Chou, T., and Talalay, P. (1984). Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. in Enz. 35 Regulation. 22, 27-55. Chou, T. , (1991) . The median-effect principle and the combination index for quantitation of synergism and antagonism, in: Synergism and antagonism in chemotherapy, T. Chou, and D.C. Rideout, eds. (San Diego, CA. : Academic Press), pp. 61-102. Clavel, F., D. Guetard, F. Brun-Vezinet, S. Chamaret, M. A. Rey, M. O. Santos-Ferreira, A. G. Laurent, C. Dauguet, C. Katlama, C. Rouzioux, D. Klatzmann, J. L. Champalimaud, and L. Montagnier. (1986) Science 233:343-346. Cleff, J.C.S., Chanas, A.C., and Gould, E.A. (1983) . Conformational changes in Sindbis glycoprotein El induced by monoclonal antibody binding. J. Gen. V ' -l. 64, 11221-1126. Coller, H.A. , diid Coller, B.S. (1987). Statistical assessment of hybridoma monoclonality after subcloning by the limiting dilution technique, in: Methods of Hybridoma Formation, A.H. Bartal, and Y. Hirshaut, eds. (Clifton, New Jersey: Humana Press), pp. 231-236. Crawford, D.H. (1985) . Production of human monoclonal antibodies using Epstein-Barr virus, in: Human Hybridomas and Monoclonal Antibodies, E.g. Engleman, S.K.H. Foung, J. Larrick, and A. Raubitschek, eds. (New York: Plenum Press), pp. 37-53. Devash, Y., Calvelli, T.A. , Wood, D.G., Reagan, K.L., and Rubinstein, A. (1990). Vertical transmission of human immunodeficiency virus is correlated with the absence of high- affinity/avidity maternal antibodies to the gpl20 principal neutralizing domain. Proc. Natl. Acad. Sci. USA. 87, 3445-3449. Dolby, T. W. , J. Devuono, and C. M. Croce. (1980) Proc. Natl. Acad. Sci. USA 77:6027-6031. Dubuisson, J. , Guillaume, J. , Boulanger, D. , Thiry, E. , Bublot, M. , and Pastoret, P. (1990). Neutralization of bovine herpervirus type 4 by pairs of monoclonal antibodies raised against two 5 glycoproteins and identification of antigenic determinants involved in neutraliziation. J. Gen. Virol. 71, 647-653. Eckhardt, L. A., S. A. Tilley, R. B. Lang, K. B. Marcu, and B. K. Birshtein. (1982) Proc. Natl. 10 Acad. Sci. USA 79:3006-3010. Emini, E.A. , Nara, P.L., Schleif, W.A. , Lewis, J.A., Davide, J.P., Lee, D.R. Kessler, J. , Conley, S., Matsushita, S., Putney, S.D., Gerety, R.J., and Eichberg, J.W. (1990) . Antibody-mediated in 15 vitro neutralization of hu a..' -' munodeficiency virus type 1 abolishes infectivity for chimpanzees. J. Virology. 64, 3674-3678. Gallo, R. , S.Salahuddin, M. Popovic, Q. Shearer, M. Kaplan, B. Haynes, T. Palker, R. 20 Redfield, J. Oleske, B. Safai, G. White, P. Foster, and P. Markham. (1984) Science 224:500- 503. Gerna, G. , Revello, M.G., Dovis, M. , Petruzzelli, E. , Achilli, G., Percivalle, E., and 25 Torsellini, M. (1987) . Synergistic neutralization of rubella virus by monoclonal antibodies to viral haemagglutinin. J. Gen. Virol. 68, 2007-2012. Girard, M. , Kieny, M.P., Pinter, A., Barre- Sinoussi, F., Nara, P., Kolbe, H., Kusu i, K. , 30 Chaput, A., Reinhart, T., Muchmore, E. , Ronco, J., i. Kaczorek, M. , Gomard, E. , Gluckman, J. , and Fultz, P. (1991) . Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl. Acad. Sci, 35 USA. 88, 542-546. Girard, M. , P. Fultz, M.P. Kieny, M. Yagello, A. Deslandres, E. Muchmore, A. Pinter, P. Nara, J. Ronco, F. Barre-Sinoussi, J. Lecocq, and J. Gluckman. (1989) Q atrie e Colloxjue Deε 'Cent Gardes ', October 26-28, Marnes-la-Coquette, France Gorny, M.K. , V.Gianakakos, S. Sharpe, and S. Zolla-Pasner. (1989) Proc. Natl. Acad. Sci. USA 86:1624-1628. Gurgo C. , Guo H.G., Franchini G., Aldovini A., Collatti E. , Ferrell K. , Wong-Staal F., Gallo R.G., Reitz M.S. Jr., Envelope Sequences of Two New United States HIV-l Isolates, (1988) Virology 4164:531-536. Harada, S., Y. Koyanagi, and N. Yamamoto (1985) Science 229:563-566. Harlow, E. , and D. Lane. (1988) in Antibodies: A laboratory manual. Cold Spring Har-/•*•-. Laboratory, Cold Spring Harbor, NY, p. 310. Ho, D.D., XL Li, E.S. Daar, T. Moudgil, N.C. Sun, D. Holton, and J.E. Robinson (June 20-24, 1990, San Francisco) Sixth International Conference on AIDS, 153. Ho, D.D., Sarngadharan, M.G. Hirsch, M.S., Schooley, R.T. , Rota, T.R., Kennedy, R.C., Chanh, T.C., and Sato, V.L. (1987). Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J. Virol. 61, 2024-2038. Homsy, J. , Tateno, M. , and Levy, J.A. (1988). Antibody-dependent enhancement of HIV infection. Lancet, i, 1285-1286. Javaherian, K., Langlois, A.J., LaRosa, G.J., Profy, A.T., Bolognesi, D.P., Herlihy, W.C., Putney, S.D., and Matthews, T.J. (1990). Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-l. Science. 250, 1590-1593. Jouault, T., Chapuis, F. , Olivier, R. , Parravicini, C. , Bahraoui, E. , and Gluckman, J.C. (1989). HIV infection of monocytic cells: role of antibody-mediated virus binding to Fc-gamma Λ- receptors. AIDS. 3, 125-133. Karpas, A., Hill, F. , Youle, M. , Cullen, V., ϊ 5 Gray, J. , Byron, N. Hayhoe, F. , Tenant-Flowers, M. , Howard, L. , Gilgen, D., J.K. Oates, Hawkins, D. , and Gazzard, B. (1988) . Effects of passive immunization of patients with the acquired immunodeficiency syndrome-related complex and 10 acquired immunodeficiency syndrome. Proc. Natl. Acad. Sci. USA. 85, 9234-9237. Kieny, M.P., Lathe, R. , Riviere, Y., Dott, K. , Schmitt, D., Girard, M. , Montagnier, L. , and Lecocq, J. (1988) . Improved antigenicity of the 15 IIIV env protein by cleavage site removal. P ^- 'n Engineering. 2, 219-225. Kimura-Kuroda, J. , and Yasui, K. (1983). Topographical analysis of antigenic determinants on envelope glycoprotein V3 (E) of Japanese 20 encephalitis virus, using monoclonal antibodies. J. Virol. 45, 124-132. Kingsford, L. (1984) . Enhanced neutralization of La Crosse virus by the binding of specific pairs of monoclonal antibodies to the Gl 25 glycoprotein. Virology. 136, 265-273. Koyanagi, Y., Miles, S., Mitsuyasu, R.T., Merrill, J.E., Vinters, H.V., and Chen, I.S.Y. (1987) . Dual infection of the central nervous system by AIDS viruses and distinct cellular 30 tropisms. Science 236, 819-822. Kozbor, D. , A. E. Lagarde, and J. C. Roder. (1982) Proc. Natl. Acad. Sci. USA 79:6651-6655. Laemmli, U. K. (1970) Nature 227:680-683. Larrick, J. W. , L. Danielεson, C. A. Brenner, 3f E. F. Wallace, M. Abrahamson, K. E. Fry, and C. A. K. Borrebaeck. (1989) Biotechnology 7:934-938. LaRosa, G.J. , Davide, J.P. , Weinhold, K. , Waterbury, J.A. , Profy, A.T., Lewis, J.A. , Langlois, A.J., Dreesman, G.R. , Boswell, R..N. , P. Shadduck, Holley, L.H. , Karplus, M. , Bolognesi, D.P., Matthews, T.J., Emini, E.A., and Putney, S.D. (1990) . Conserved sequence and structural elements in the HIV-l principal neutralizing determinant. Science. 249, 932-935. Lasky, L.A. , Nakamura, G., Smith, D.H., Fennie, C. , Shimasaki, C. , Patzer, E. , Berman, P. Gregory, T. , and Capon, D.J. (1987). Delineation of a region of the human immunodeficiency virus type 1 gpl20 glycoprotein critical for interaction with the CD-4 receptor. Cell. 50, 975-985. Lasky, L.A. , J.E. Groopman, C.W. Fennie, P.M. Benz, D.J. Capon,D.J. Dowbenko, G.R. Nakamura, W.M. Nunes, M.E. Renz, and P.W. Berman. (1986) Science 233:209-212. Layne, S.P., Spouge, J.L., and Dembo, M. (1989) . Quantifying the infectivity of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 86, 4644-4648. Levy, J. A., A. D. Hoffman, S. M. Kramer, J. A. Landis, J. M. Shimabukuro, and L. S. Oshiro. (1984) Science 225:840- 842. Leonard, C. K. , M. W. Spellman, L. Riddle, J. N. Thomas, and T. J. Gregory. (1990) J. Biol. Chem. 265:10373-10382. Ljunggren, K. , Bottiger, B., Biberfeld, G. , Karlson, A., Fenyo, E. , and Jondal, M. (1987). Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. J. Immunol. 139, 2263-2267. Lussenhop, N.O., Goertz, R. , Wabuke-Bunoti, "ϊ. , Gehrz, R., and Kara, B. (1988). Epitope analysis of human cytomegalovirus glycoprotein complexes using murine monoclonal antibodies. Virology. 164, 362-372. Myers, G. , A. Rabson, S. Josephs, T. Smith, J. Berzofsky, and F. Wong-Staal (eds.) (1989) Human Retroviruses and AIDS, LA-UR, 89-743, Los Alamos National Laboratory, Los Alamos. Olshevsky, U., Helseth, E. , Gurman, C. , Li, J. , Haseltine, W. , and Sodroski, J. (1990). Identification of individual human immunodeficiency virus type 1 gpl20 amino acids important for CD-4 receptor binding. J. Virol. 64, 5701-5707. Orlandi, R. , D. H. Gussow, P. T. Jones, and G. Winter. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837. Parham, P. (1986) In Cellular Immunology 4th Ed. (ed. D.M Weir), vol. 1, chap. 14. Blackwell Scientific Publications, California. Peiris, J.S.M., Porterfield, J.S., and Roehrig, J.T. , (1982). Monoclonal antibodies against the flavivirus West Nile. J. Gen. Virol. 58, 283-289. Pinter, A., W. J. Honnen, S. A. Tilley, C. Bona, H. Zaghouani, M. K. Gorny, and S. Zolla- Pazner (1989) J. Virol. 63:2674-2679. Pinter, A., and W. J. Honnen. (1988) J. Virology 62:1016-1021. Popovic, M. , M. G. Sarngadharan, E. Read, and R. C. Gallo. (1984) Science 224:497-500. Posner, M. , Mukherjee, M. , Hideshima, T. , Cannon, T.C., and Mayer, K. (1990). Development of an IgG-l human monoclonal antibody that neutralizes HIVl infectivity and binding and reacts with a cell surface antigen expressed by HIVl infected cells. Sixth International Conference on AIDS, San Francisco. Abstract, Th.A.77. Putney, S.D., T.J. Matthews, W.G. Robey, D.L. Lynn, M. Robert-Guroff, W.T. Mueller, A.J. Langlois, J. Ghrayeb, S.R. Petteway, K.J. Weinhold, P.J. Fischinger, F. Wong-Staal, R.C. Gallo, and D.P. Bolognesi (1986) Science 234:1392- 1395. Ratner, L. , W. Haseltine, R. Patarca, K. J. Livak, B. Starcich, S. F. Josephs, E. R. Doran, J. A. Rafalski, E. A. Whitwhoen, K. Baumeister, L. Ivanoff, S. R. Petteway, M. L. Pearson, J. A. Lautenberger, T. S. Papas, J. Ghrayeb, N. T. Chang, R. C. Gallo, and F. Wong-Staal. (1985) Nature 313:277-284. Raubitschek, A. A. (1985) in Human Hybridomas and Monoclonal Antibodies, E.G. Engleman, S.K.H. Foung, J. Larrick, and A. Raubitschek (ed.) Plenum Press, New York, P. 454-455. Ravetch, J. V., U. Siebenlist, S. Korsmeyer, T. Waldmann, and P. Leder. (1981) Cell 27:583-591. Robert-Guroff, M. , Brown, M. , and Gallo, R.C. (1985) . HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature. 316, 72-74. Robinson, W.E., Kawamura, T. , Lake, D. , Masuho, Y., Mitchell, W.M. , and Hershy, E.M. (1990) . Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-l) glycoprotein gp41 enhance HIV-l infection in vitro. J. Virol. 64, 5301-5305. Robinson, J.E., D. Holton, S. Pacheco-Morell, J. Liu, and H. McMurdo. (1990) AIDS 4:11-19 Robinson, J.E., Holton, D., Pacheco-Morell, S., Liu, J. , and McMurdo, H. (1990). Identification of conserved and variant epitopes of human immunodeficiency virus type 1 (HIV-l) gpl20 by human monoclonal antibodies produced by EBV-transformed cell lines. AIDS Res. Human Retroviruses. 6, 567-579. Rook, A.H., Lane, H.C., Folks, T. , McCoy, S., Alter, H. , and Fauci, A.S. (1987). Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. J. Immunol. 138, 1064-1067. Russell, P.H. (1986). The synergistic neutralization of Newcastle Disease virus by two monoclonal antibodies to its haemagglutinin- neuraminidase protein. Arch. Virol. 90, 135-144. Sanchez-Pescador, R. , M. D. Power, P. J. Barr, K. S. Steimer, M. M. Stempten, S. L. Brown-Shimer, W. W. Gee, A. Renard, A. Randolph, J. A. Levy, D. Dina, and P. A. Luciw. (1985) Science 227:484-492. Scott, C.F., Silver, S., Profy, A.T., Putney, S.D., Langlois, A., Weinhold, K. , and Robinson, J.E. (1990). Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gpl20 and neutralizes the human T- lymphotropic virus type III MN strain. Proc. Natl. Acad. Sci. USA. 87, 8597-8601. Shaw, G. M. , B. H. Hahn, S. K. Arya, J. E. Groop an, R. C. Gallo, and F. Wong-Staal. (1984) Science 226:1165-1171. Siadak, A. W. , and M. E. Lostrom. (1985) in Human Hybridomas and Monoclonal Antibodies, E.G. Engleman, S.K.H. Foung, J. Larrick, and A. Raubitschek (ed.). Plenum Press, New York, p. 167-185 Starcich, B. R. , B. H. Hahn, G. M. Shaw, P. D. McNeely, S. Modrow, H. Wolf, E. S. Parks, W. P. Parks, S. F. Josephs, R. ( . Gallo, and F. Wong- Staal. (1986) Cell 45:637-648. Sun, N. , Ho, D.D., Sun, C.R.Y., Liou, R. , Gordon, W. , Fung, M.S.C., Li, X., Ting, R.C, Lee, T. , Chang, N.T., and Chang T. (1989). Generation and characterization of monoclonal antibodies to the putative CD-4-binding domain of human immunodeficiency virus type 1 gpl20. J. Virol. 63, 3579-3585. Takeda, A., Tuazon, C.U. , and Ennis, F.A. (1988) . Antibody-enhanced infection by HIV-l via Fc receptor-mediated entry. Science. 242, 580- 583. Teng, N. N. H., K. S. Lam, F. C. Riera, and H. S. Kaplan. (1983) Proc. Natl. Acad. Sci. USA 80:7306-7312. Volk, W.A., Snyder, R.M., Benjamin, D.C., and Wagner, R.R. (1982) . Monoclonal antibodies to the glycoprotein of vesicular stomatitis virus: Comparative neutralizing activity. J.Virol. 42, 220-227. van Heyningen, V., and S. van Heyningen. (1987) in Methods of Hybridoma Formation, A.H. Bartal, and Y. Hirshaut (ed.). Humana Press, Clifton, New Jersey, p. 399-411. Weiss, R.A. , Clapham, P.R., Cheingsong-Popov, R. , Dalgleish, A.G., Came, CA. , Weller, I.V.D., and Tedder, R.S. (1985). Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature. 316, 69-71. Zolla-Pazner, S., Gianakakos, V., Williams, C, Sharpe, S., and Gorny, M.K. (1990). Production of human monoclonal antibodies against the V3 loop of gpl20. Sixth International Conference on AIDS, San Francisco. Abstract, Th.A. 75.

Claims: What is claimed is: * 1. A combination of Abs consisting essentially of (a) Abs specific for the V3 loop of HIV-l \ envelope glycoprotein gpl20; and 5 (b) Abs which are specific for the CD-4 binding site of HIV-l envelope glycoprotein gpl20; which combination of antibodies is capable of synergistically neutralizing HIV-l infectivity. 2. A combination of human mAbs comprising 10 (a) human mAbs specific for the V3 loop of HIV-l envelope glycoprotein gpl20; and (b) human mAbs which are specific for the CD- 4 binding site of HIV-l envelope glycoprotein gpl20; 15 which combination of antibodies is capable of synergistically neutralizing HIV-l infectivity. 3. A combination of Abs consisting essentially of (a) human mAbs which competitively inhibit the binding of antibodies produced by the cell 20 line 1125H to gpl20; and (b) human mAbs which competitively inhibit the binding of antibodies produced by the cell line 4117C to gpl20. 4. The combination of human mAbs of claim 3 25 wherein the human mAbs which are specific for the CD-4 binding site (a) neutralize HIV-l strains IIIB, MN, SF-2 and RF; (b) do not react with LAV-2; 30 (c) react with both acetone and methanol- fixed HIV-l infected cells; (d) react with formaldehyde-fixed HIV-l infected cells; (e) react with live HIV-l infected cells; (f) possess high affinity for gpl20; (g) do not react with the hypervariable V3 loop of gpl20; (h) are inhibited from binding to gpl20 in the presence of CD-4; (i) achieves 50% neutralization of the MN HIV-l strain at a concentration of about lμg/ml in the absence of other antibodies; and (j) does not react with HIV-l which has been treated to reduce disulfide bonds of the virus' protein. 5. The combination of claim 3 comprising human mAbs obtained from cell line 1125H and human mAbs obtained from cell line 4117C 6. The combination of human mAbs of claim 3 comprising (a) human mAbs having the identifying characteristics of those obtained from the cell line 1125H; and (b) human mAbs having the identifying characteristics of those obtained from the cell line 4117C 7. A combination of human mAbs comprising (a) human mAbs substantially having the epitope specificity of antibodies produced by the cell line 1125H; and (b) human mAbs substantially having the epitope specificity of antibodies produced by the cell line 4117C 8. The combination of human mAbs of any of claims 1 through 7 which achieves at least about 95% neutralization of about 1 x 10 4 infectious units of the MN strain of HIV-l at a concentration of about 0.5 micrograms/ml. 9. The combination of any of claims 1 through 7 which neutralizes about 95% of 1 x 10 4 infectious units of the MN strain of HIV-l at a concentration of 0.5 micrograms/ml. 10. The combination of any of claims 1 through 7 having a combination index value less than 1 at 50% neutralization of 10 4 -10 5 infectious units of HIV at a concentration no greater than approximately 100 micrograms per ml of the combination 11. The combination of any of claims 1 through 7 having a combination index value less than .5 at 50% neutralization of 10 4 -10 5 infectious units of HIV a concentration no greater than approximately 100 micrograms per ml of the combination. 12. The combination of any of claims l through 7 wherein the antibodies are in a molar ratio of 1:1. 13. The combination of human mAbs of any of claims 1 through 7 which achieves 50% neutralization of about 1 x 10 4 infectious units of the MN strain of HIV-l at a concentration of about 0.15 micrograms/ml. 14. The combination of any of claims 1 through 7 which neutralizes about 50% of 1 x 10 4 infectious units of the MN strain of HIV-l at a concentration of 0.15 micrograms/ml. 15. The combination of any of claims 1 through 7 which also synergistically neutralizes the SF-2 strain. 16. The combination of any of claims 1 through 7 which neutralizes at least about 95% of 1 x 10 4 infectious units of the SF-2 strain of HIV-l at a concentration of about 7 micrograms/ml. 17. The combination of any of claims 1 through 7 which achieves 50% neutralization of about 1 x 10 4 infectious units of the SF-2 strain of HIV-l at a concentration of about 1.2 micrograms/ml. 18. A cell line, which cell line produces human monoclonal antibodies specific for the V3 loop of HIV-envelope glycoprotein gpl20, which antibodies have the epitope specificity of those produced by the cell line 4117C to gpl20. 19. The cell line of claim 18 which is an EBV transformed human cell line. 20. The cell line of claim 19 which is an immortalized cell line. 21. Human monoclonal antibodies produced by the cell line of claim 18. 22. The human monoclonal antibodies of claim 21 substantially having the specificity of those produced by the cell line 4117C 23. Human monoclonal antibodies of claim 21 having the identifying characteristics of those produced by the cell line 4117C 24. A method of treating HIV-l infection comprising administering an effective amount of the combination according to any of claims 1 through 7 to an individual. 25. The method of claim 24 wherein the monoclonal antibody to the CD-4 binding site and the monoclonal antibody to the V-3 region are administered sequentially. 26. A method of preventing HIV-l infection comprising administering an effective amount of the combination according to any of claims 1 through 7 to an individual. 27. A therapeutic reagent comprising the combination according to any of claims 1 through 7 in a physiologically compatible solution. 28. A transformed cell line, which cell line produces a human monoclonal antibody specific for HIV-envelope glycoprotein gpl20, which antibody is specific for a gpl20 epitope which is conserved among the IIIB, MN, SF-2, and RF HIV-l strains. 29. An immortalized human cell line, which cell line produces a human monoclonal antibody specific for HIV-envelope glycoprotein gpl20, which antibody achieves at least about 50% neutralization of about 1 x 10 4 infectious units of the MN HIV-l strain at a concentration of about lμg/ml. 30. An immortalized human cell line, which cell line produces a human monoclonal antibody specific for HIV-envelope glycoprotein gpl20, which antibody achieves about 90% neutralization of about l x 10 4 infectious units of the MN HIV-l strain at a concentration of about lμg/ml. 31. An immortalized human cell line, which cell line produces a human monoclonal antibody specific for HIV-envelope glycoprotein gpl20, which antibody (a) neutralizes HIV-l strains IIIB, MN, SF-2 and RF; (b) possesses high affinity for gpl20; (c) does not react with the hypervariable V3 loop of gpl20; and (d) is inhibited from binding to gpl20 in the presence of CD-4. 32. A transformed human cell line, which cell line produces a monoclonal antibody specific for HIV- envelope glycoprotein gpl20, which antibody (a) neutralizes HIV-l strains IIIB, MN, SF-2 and RF; (b) does not react with LAV-2; (c) reacts with both acetone and methanol- fixed HIV-l infected cells; (d) reacts with formaldehyde-fixed HIV-l infected cells; (e) reacts with live HIV-l infected cells; (f) possesses high affinity for gpl20; (g) does not react with the hypervariable V3 loop of gpl20; (h) is inhibited from binding to gpl20 in the presence of CD-4; (i) achieves 50% neutralization of 1 x 10 4 infectious units the MN HIV-l strain at a concentration of about lμg/ml; and (j) does not react with HIV-l which has been treated to reduce disulfide bonds of the virus' protein. 33. The cell line of claim 31 or 32 which is immortalized by EBV transformation. 34. The cell line of claim 31 or 32 wherein the antibody has a light chain isotype of the kappa type and has a heavy chain isotype of the IgGl type. 35. An EBV-transformed cell line as in claim 32 having the identifying characteristics of the cell line 1125H deposited under ATCC# CRL10582. 36. An EBV-transformed cell line as in claim 32 which is cloned from cell line 1125H deposited under ATCC CRL10582. 37. Human monoclonal antibodies specific for a gpl20 epitope which is conserved among the IIIB, MN, SF-2, and RF HIV-l strains. 38. The human monoclonal antibodies of claim 37 which achieve about 90% neutralization of 1 x 10 4 infectious units of the MN HIV-l strain at a concentration of about lμg/ml. 39. Human monoclonal antibodies which are specific for HIV-envelope glycoprotein gpl20, which antibodies (a) neutralize HIV-l strains IIIB, MN, SF-2 and RF; (b) possess high affinity for gpl20; (c) do not react with the hypervariable V3 loop of gpl20; and (d) are inhibited from binding to gpl20 in the presence of CD-4. 40. The human monoclonal antibodies of claim 39 having the epitope specificity of those produced by cell line 2154B.1 deposited under ATCC# CRL10581. 41. The human monoclonal antibodies of claim 40 which are obtained from cells cloned from cell line 2154B.1 deposited under ATCC# CRL10581. 42. The human monoclonal antibodies of claim 39 having the epitope specificity of those produced by cell line 2173C deposited under ATCC# CRL10580. 43. The human monoclonal antibodies of claim 42 which are obtained from cells cloned from cell line 2173C deposited under ATCC# CRL10580. 44. The human monoclonal antibodies of claim 39 having the epitope specificity of those produced by cell line 1125H deposited under ATCC# CRL10582. 45. The human monoclonal antibodies of claim 44 which are produced by cells cloned from cell line 1125H deposited under ATCC# CRL10582. 46. Human monoclonal antibodies which are specific for HIV-envelope glycoprotein gpl20, which antibodies (a) neutralize HIV-l strains IIIB, MN, SF-2 and RF; (b) do not react with LAV-2; (c) react with both acetone and methanol- fixed HIV-l infected cells; (d) react with formaldehyde-fixed HIV-l infected cells; (e) react with live HIV-l infected cells; (f) possess high affinity for gpl20; (g) do not react with the hypervariable V3 loop of HIV-l; (h) are inhibited from binding to gpl20 in the presence of CD-4; (i) achieve 50% neutralization of 1 x 10 4 infectious units of the MN HIV-l strain at a concentration of about lμg/ml; and (j) do not react with HIV-l which has been treated to reduce disulfide bonds of the virus' protein. 47. The human monoclonal antibodies of claim 46 having a light chain isotype of the kappa type and have a heavy chain isotype of the IgGl type. 48. A therapeutic agent comprising the human monoclonal antibodies of any of claims 37 through 47 further having a toxin attached thereto. 49. A method of screening using monoclonal antibodies in order to determine a polypeptide sequence for use as a vaccine against HIV-l, characterized in using a monoclonal antibody of any of claims 37 through 47 for screening. 50. A vaccine comprising an antigen which consists of an epitope for which the antibodies of any of claims 40 through 45 are specific, which antigen rs capable of eliciting an immune response which consists essentially of the production of antibodies which have the epitope specificity of those antibodies, in combination with a pharmaceutically acceptable carrier. 51. A kit for determining the presence of antibodies against an epitope recognized by the monoclonal antibodies of any of claims claim 37 through 47, which kit comprises the monoclonal antibodies, a solid phase on which is coated an antigen which the monoclonal antibodies are specific for, and means for detecting the formation of a complex between the monoclonal antibodies and the antigen. 52. A method of preventing or treating HIV-l infection comprising administering an effective amount of human monoclonal antibodies of any of claims 37 thorugh 47 to an individual.

Inventors: PINTER ABRAHAM, TILLEY SHERMAINE A, PINTER, ABRAHAM, TILLEY, SHERMAINE, A.
Applicants: NEW YORK HEALTH RES INST, THE PUBLIC HEALTH RESEARCH INSTITUTE OF THE CITY O
Application year: 1991
Main classification: C07K15
IPC codes: A61K38, A61K39, A61P31, C07K14, C07K16, C12N5, C12N15, C12P21, G01N33